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CHAPTER 1: INTRODUCTION
Celiac Disease (CD) is an autoimmune condition with a 3:1 female predilection in which
ingestion of gluten triggers immune mediated damage to the lining of the small intestine in
susceptible individuals and confers a 2-4 fold increased mortality risk. CD is relatively common
with a global incidence rate estimated at 1%. However, to diagnose it, patients are often
required to provoke a potentially harmful immune response by eating a gluten-rich diet for a
period of time. The only treatment is a gluten free diet (GFD). (Singh et al., 2018)
Although prevalence rates for Celiac Disease are estimated at 1% globally, actual
prevalence may be much higher due to an average time to diagnosis of 4-11 years(Green et al.,
2001). In fact, in the USA an estimated 3 million people have Celiac but only 90,000 of them
are diagnosed.(CeliacDiseaseCenter, 2015)

Part of the delay in diagnosis relates to the

heterogeneous symptoms caused by CD, the fact that it can begin at any age, and that the only
reliable risk stratification demographics are gender, a positive family history of CD, and having
Type I diabetes. Clinical signs may be limited in nature to nongastrointestinal thus making
accurate diagnosis more difficult.
CD has a strong genetic predisposition and from early studies appeared to have a
Caucasian predominance. However recent data shows that ethnicity may not be a reliable
demographic risk factor for CD. Asians, particularly south-East Asians have some of the lowest
CD rates, with China reporting 18 cases in 1.3 billion people (Burkhardt et al., 2018). However
India‟s rates, while previously reported as lower, have risen to 1%, the global mean. Finland,
Italy, New Zealand, Israel, Northern Ireland and Iran all have prevalence rates reported near
1%. One of the highest currently known prevalence rates is 5.6% in the African
Saharawi(Burkhardt et al., 2018). As gluten ingestion is thought to be required for the
development of CD, it‟s possible that shifts in diet from more culturally traditional diets (possibly
lower in gluten) to more globalized diets may affect prevalence rates.

Conversely, the

percentage of people without a diagnosis of CD choosing to eat a gluten free diet in the US and
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Canada has risen faster than CD prevalence in both countries, which may artificially lower
prevalence data if such patients never seek a diagnosis of CD.(Singh et al., 2018)
While CD is already a relatively common illness, its prevalence appears to have been
rising globally over the past 40 years. CD prevalence rates doubled from the 1974 to 1989 in
the US and between 1980 and 2000 in Finland. In Scotland, the prevalence of CD increased
6.4 fold between 1990 and 2009. Studies in Algeria, Czech Republic, India, Israel, Mexico,
Malaysia, Saudi Arabia, Sweden, Portugal, and Turkey showed serological prevalence ranged
from 2.1%-8.5%.(Singh et al., 2018) These statistics strongly suggest that worldwide prevalence
of CD is increasing at a rate that exceeds diagnostic advances.(Burkhardt et al., 2018; Ivarsson
et al., 2010; Singh et al., 2018)
Medical testing for CD is less than ideal. First steps include ordering blood antibody
tests that can be falsely negative in a person eating a gluten free diet, so such patients are
required to eat gluten for up to 8 weeks to provoke the autoimmune response and facilitate
antibody detection. For this reason, the rising popularity of a gluten free diet (GFD) and the
variation in reasons and applications of the diet presents an additional diagnostic &
epidemiological complication. Many people eating a “gluten free diet” absent strict medical
instruction, fail to eliminate all gluten from their diet. This may potentially mislead their
physicians by removing CD from consideration. One study estimates that 30% of all Americans
and Canadians are attempting a gluten-free diet, which far exceeds the current estimates of CD
in the population. Even if individuals with various levels of gluten sensitivities and/or allergies
were included, it is likely that the population of people who medically require a GFD is
significantly less than 30%. Additionally, ingesting gluten can worsen inflammation in the
intestine, cause significant symptoms and disrupt the quality of life of the patient. Even with a
positive CD antibody test, the “gold standard” for confirming a CD diagnosis is duodenal biopsy
showing a specific pattern of damage to the intestinal lining. Upper endoscopy with biopsy of
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damaged tissue is expensive, time consuming, invasive, and can potentially leave areas of
damage that do not heal properly due to the inflammation present.
History
Genetic markers in the bones of a woman who lived 2000 years ago make her the first
known individual with CD.

The name Celiac was first derived from the Greek word „kolis‟

meaning „stomach‟ and then from the Latin word „coeliacus‟ meaning „person with painful
bowels‟. It was first recorded by Aretaeus in the second century to describe a stomach condition
resulting in prolonged diarrhea leading to malnutrition, pale skin, gaseous diarrhea, muscle
weakness, and body-wide atrophy, symptoms still observed in CD today.(Marsh, 1995; Paveley,
1988).
In the late 1800‟s, Adolf Baginsky performed histologic studies on children and infants
suffering from a condition termed „infantile atrophy‟ that presented with failure to thrive, pale
skin, thin legs and buttocks, prominent abdomen, sensitive gut, and “loose, greasy feces”.
Baginsky noted most patients with the illness were irritable, moody, and lethargic with a high
susceptibility to infections. Baginsky‟s histological findings pointed to a damaged intestine as
the cause of the systemic atrophy, specifically in well-fed infants. At the time, infantile atrophy
was a clinical syndrome caused by several different gut conditions, including what would later
be deemed Celiac disease by Dr Samuel Jones Gee.(Toscano, 2004; Turner et al., 2015)
In the late 1800s, Dr. Samuel Jones Gee renamed infantile atrophy as the Coeliac
Affliction, a term coined by a Greek physician. In October 1887, Gee gave a lecture citing the
fecal condition as the basis for the diagnosis of Coeliac Affliction noting patients‟ faeces, were
“loose, not formed but watery; more bulky than the food taken would seem to account for; pale
in colour, as if devoid of bile; yeasty, frothy, an appearance probably due to fermentation;
stinking, stench often very great, the food having undergone putrefaction rather than
concoction”(Paveley, 1988).
treatment.

Gee blamed starchy foods, and recommended diet control as

The diets were not necessarily gluten-free, but occasionally a diet consisting of all
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mussels or all bananas yielded improvement. Many of Dr. Gee's clinical observations were
corroborated two years later in Edinburgh by another English physician, Dr. R. A. Gibbons, who
studied infants who died of the disease. Dr. Gibbon‟ post-mortems showed “no wasting of the
mucous membrane, no ulceration, and no wasting of Lieberkuhn's follicles” to indicate nutritional
issues. Instead, it suggested the issue to be one of digestion of food and the absorption of
damaging elements due to this deviant digestion caused by the nervous system and its
interaction with the liver, pancreas and stomach. In 1904, Dr. Cheadle agreed with the nervous
system involvement in Coeliac Affliction and re-named the condition Acholia after noting the
presence of fat and absence of bile in the stool. He also noted a possible dental correlation and
included gum lancing in his treatment regimens.(Dickson et al., 2006; Marsh, 1995; Paveley,
1988)
Several more breakthroughs continued in the early 1900s. In 1908, the idea that Acholia
was caused by intestinal inflammation was published by Dr. Herter, who restated in 1918 the
correlation with starch, particularly bread, as a source of symptoms.

The first successful

treatment plan for Acholia was developed by Dr. Sidney Haas in 1924. He combined a banana
diet with colonic irrigation and castor oil to treat and presumptively cure eight children. This
cure was defined by clinical resolution of the symptoms as intestinal biopsies would not be
available until 1940s. Like the gluten free treatment today, this cure was only successful as
long as the child remained on the diet.

Dr. Haas‟ diet excluded starches such as bread,

potatoes, cereals and crackers, but also sucrose and other sugars except those found in
bananas.

This was largely due to Puerto Rican farmers whose diet used bananas as a

carbohydrate source as opposed to bread. Since the diets were incidentally gluten-free, They
were successful in arresting the symptoms of CD. It wasn‟t until the food shortage during World
War II that the connection between CD and wheat was noticed. A Dutch pediatrician, Dr.
William-Karel Dirke, noted that during the bread shortage in the Netherlands, those with CD
improved remarkably until a Swedish effort to combat hunger provided bread to the Dutch

5
population. Dirke had considered the causal connection as early as 1930. With the additional
evidence, Dirke‟s team studied bread more thoroughly and concluded that gluten, not starch,
was the toxic element triggering CD symptoms. Haas' banana diet remained popular despite
Dirk's evidence that a less restrictive diet would alleviate symptoms of CD. (Marsh, 1995;
Paveley, 1988; Smits, 1989; Turner et al., 2015)
In 1954, Dr. J.W Paulley began a line of research into the normal biopsy of the jejunal
mucosal layer of the intestine. Gastric biopsies on live patients became available only after the
1950s and provided a histological method of diagnosing many GI condition, including CD. In
1955, groups in Argentina and England accessed the duodenum for biopsies in live patients,
lesions which would eventually define the pathology of CD. (Paveley, 1988)
Throughout the 1960s and 1970s doctors noticed a correlation between certain
duodenal biopsy pathology and various other symptoms like dermatitis herpetiformis and gluten
ataxia. Additionally, the discovery of α gliadin as the toxic substance in gluten occured. Early
immunology work in 1972 correlated HLA and CD. In the mid 1980‟s, research demonstrated
that not all children with CD demonstrate outright symptoms, leading to the possibility of an
Asymptomatic CD diagnosis.(Cacciari et al., 1983) In 1983, the presence of specific antibodies
during CD was discovered. (Gasbarrini et al., 2014) By the mid 1990s, research found a strong
correlation between anemia and CD and that certain HLA-types are associated with CD. The
endoscopic criteria were revised in 1990.(Auricchio and Troncone, 1996; Sollid et al., 1989)
Also, the higher incidence rate in females vs.males became apparent.(Cirillo et al., 1995) By
1999, a duodenal biopsy screening was suggested for women suspected to have CD. In 2005,
serology and duodenal biopsy became the standard for diagnosing CD as set forth by the North
American Society for Pediatric Gastroenterology, Hepatology and Nutrition.(Hill et al., 2005)
General Celiac Overview
Celiac Disease results from a complicated interaction between the digestive system and
the immune system in the presence of Gluten. Figure 1 shows a flowchart of all the interactions

6
involved in the basics of CD. Digestions starts in the mouth and proceeds through the stomach
and into the three sections of the small intestine before the remaining food particles are
excreted through the colon. The immune system, beginning on the lower left corner of the
flowchart, sends immature cells from the bone marrow either to the stromal of that bone marrow
where they develop into B-cells or to the thymus where they develope into T-cells. Both these
cells enter the systemic immune system. At each section of the small intestine the endothelium
interacts with digested gluten polypeptides. This interaction results in the activation of Cytotoxic
T-cells lining the endothelium causing endothelium damage which can cause bacteria to enter
the liver duct, thus increasing the chance of Chronic Active Hepatitis. Additionally, the gluten
polypeptides interact with the zonulin pathway to open the tight junctions in the endothelium,
also causing endothelium damage. Both this pathway and the endothelium damage itself allow
unwanted particles to enter the lamina from the intestine. Additional polypeptides enter the
lamina through the normal physiological transfer systems where they interact with tTG2 to
activate the adaptive immune system. The genes that code the receptors in the T-cells at this
stage are identified in a Genetic Diagnosis. The resultant activation of B-cells activates the
immune response to injury, including inflammation and cellular proliferation. The activated Bcells also produce quantities of tTG2 antibodies, whose presence in serum is identified in a
Serological Diagnosis. The immune response to injury and the previous endothelium damage
both cause villous blunting in the small intestines. This is identified in a Endoscopic Diagnosis.
This villous blunting, when in the duodenum, decreases or halts the production of the hormone
that induces the gall bladder to secrete bile. This process in the small intestines promotes bilary
production by the liver, which is fed into the Gall bladder causing inflation and possibly Primary
Bilary Cirrhosis. The villous blunting in any section of the small intestine decreased the nutrition
transfer efficiency. This causes multiple symptoms such as general nutritional deficiency, failure
to thrive, organ atrophy, fetal development retardation during pregnancy and bone matrix
porosity. The presence of tTG2 antibodies also causes several symptoms such as Dermatitis
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Herpiformis, additional bone matrix porosity and several neuropathies. A combination of these
symptoms are identified as a Symptomatic Diagnosis.

8

Figure 1: Flow Chart of Celiac Disease. The digestion system starts in the upper left and the immune
system starts in the lower left. The legend in the upper right identifies symbols for processes in the
digestion system, immune system, and physiological pathways. Additionally the color of the arrows indicate
the normal activity, activity during the celiac reaction and the pathology following CD.
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CHAPTER 2: DIGESTION OVERVIEW
Celiac Disease has been associated with food intake since the 2nd century making the
study of digestion an integral part of understanding CD.
Throat and stomach
Food particles that enter the digestive tract travel through several digestive processes
before encountering the intestine.

In the mouth, mastication and saliva start the digestive

process by breaking food into smaller particles and breaking polysaccharides into simple
sugars. Salivary pH and enzymes provide some protein degradation and bacterial protection for
the body. Once masticated, food enters the stomach. Hydrochloric acid kills most microbes
and lowers the pH of the stomach contents to change the oxidation state of iron.

It also

activates pepsin from the pepsinogen released by the stomach, which breaks proteins into
smaller polypeptides. Intrinsic factor (IF) is also released into the stomach contents to bind
vitamin B12.
Pepsin is a class of aspartic peptidase present in human gastric juice(Roberts, 2006).
Aspartic peptidases attack scissile peptide bonds, utilizing a water molecule to cleave proteins.
This particular peptidase is categorized as Aspartic due to the Asparagine residues that act as
ligands for the activated water molecule. These peptidases are divided into clans.

Pepsin

belongs in Clan AA under Family A1, a group of bi-lobed enzymes with Asp residues at the
active sites. Pepsin activity normally requires a pH below 4.5 and the peptidase denature above
a pH of 7.0. Human gastric juice, found mainly in the stomach and composed largely of HCl,
maintains a pH between 1.5 and 3.5 under normal conditions. Food spends up to 2 hours being
digested in the stomach, making the stomach luminal pH crucial to food digestion. The main
pepsins found in human gastric juice are pepsin A, pepsin C, cathepsin D and cathepsin E.
The stomach consists of 3 layers of muscle each with a unique fiber orientation. They
allow the stomach to contract and relax in multiple directions to physically break food boluses
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into smaller particles and thoroughly mix them with the HCl, pepsin, and IF into a liquid
substance referred to as chyme.
Small intestine
From the stomach, chyme flows through the pyloric sphincter into the small intestine to
be further digested. It is either absorbed as nutrition or transformed into waste products and
excreted by the colon. The luminal surface of the small intestine is covered in epithelial cells
called enterocytes.

These specific enterocytes absorb nutrients from the chyme, including

peptides with single, double and triple residue chains.(Caminero et al., 2014) To increase
absorption, the lining of the small intestine utilize villi, small fingerlike projections, to create a
convoluted wall which maximizes surface area in contact with luminal contents in a small
space. The layer of enterocytes covering the villi themselves have additional small projections
formed in the luminal surface membrane called microvilli, collectively referred to as the brush
border.(Hall and Guyton, 2011)
Utilizing this brush border, digested proteins in the form of single amino acids are
transported into the bloodstream for use. Dipeptides and tripeptides undergo further hydrolysis
into single amino acids during transport through the PEPT-1 channel before their release into
the bloodstream. Larger proteins left in the intestinal lumen are thought to participate in the
lifecycle of the microbiota present in the intestine. These microbiota also synthesize peptides
for the body to digest.(Caminero et al., 2014) The small intestine is divided into three sections:
duodenum, jejenum and ileum, in order of digestion.
Pancreas and Duodenum
From the stomach, chyme passes through the pyloric sphincter into the duodenum, the
first segment of the small intestine. There, a mixture of bile (produced by the liver, stored and
excreted by the gallbladder) and enzymes from the pancreas enter the duodenum through the
Ampulla of Vater and mix with the chyme. The acidic flow from the stomach also signals
secretion of cholecystokinin from the duodenum into the pancreas triggering the release of
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proenzymes, including trypsinogen and chymotrypsinogen which become trypsin and
chymotrypsin respectively upon activation.

Both of these enzymes use a catalytic triad of

Histidine, Serine and Aspartate to cleave proteins for digestion. Cholecystokinin also signals
the contraction of the gallbladder and release of bile into the small intestine which, among other
activities, emulsifies fat for digestion.

A wide variety of additional pro-enzymes in the bile

become activated by trypsin in the duodenum and further digest proteins, carbohydrates, fats,
and nucleic acids.

Elastase, carboxypeptidase A, and carboxypeptidase B, three other

enzymes released by the pancreas, activate in the same manner to further break down proteins
into smaller polypeptides(6-8 residues). Additionally, the release of secretin from the endocrine
system induces the release of bicarbonate from the pancreas and alkaline secretion from
Brunner‟s Glands. This raises the pH of the chyme to above 4.3, which protects the small
intestine and decreases the activity of the peptidases still present from the stomach. As the
chyme travels further through the small intestine, the pH can get as high as 7.0. This denatures
most pepsin compounds, which are still able to digest proteins at a pH of 5.0.
Jejunum
Following the duodenum, chyme enters the jejunum which contains the highest number
of villi on the intestinal walls and is responsible for the majority of the nutritional absorption in
the small intestine. The jejunum is also the longest section of the small intestine, and is the only
section that lacks discrete lymphoid tissue, instead containing lymphocytes throughout the
endothelium in line with its sole focus on nutrition absorption. The endothelium separates the
chyme from blood vessels that carry nutrition to its final destination. This passage flows through
the hepatic portal vein to the liver for processing into the bloodstream.
Ileum
From the jejunum, chyme flows into the Ileum, whose endothelium has fewer, flatter villi
and lymphoid tissue aggregates called Peyer‟s Patches.

Most of the remaining digestible

nutritients, fatty acids, cholesterol and bile are absorbed from the chyme as needed prior to
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traversing the ileocecal valve into the colon as waste. Bile is reabsorbed in the terminal ileum
along with cholesterol and hormones like secretin and cholecystokinin, which help to regulate
hepatic bile production and energy homeostasis.
Nutrition Absorption
Most nutrients in the small intestine are present in the form of ions, mono/bi/trisaccharides, amino acids and short peptides, fiber, chylomicrons, or triglycerides. The small
intestine absorbs necessary nutrition from the intestinal lumen into the bloodstream through
contact between villi and the chyme. The mucosal epithelium is actually structured in a way that
exponentially increases the effective surface area of the small intestine in contact with the
luminal contents, facilitating increased absorption of nutrients. The epithelium of the small
intestine is made up of repetitive ridges of tissue called valvulae conniventes, which increase
luminal surface area 3x. On the surface of the valvulae conniventes are villi, 1 mm tube-like
projections of epithelial cells containing capillaries and lymphatic ducts at their core. These
villous projections often lie close enough to each other to touch and increase the surface area of
the intestinal epithelium an additional 10 fold. On the epithelial surface of each enterocyte
present on the villi are over 1000 microvilli, each 1 um long, collectively called the brush border.
This dense forest of microvilli increases the luminal surface area of the intestine a further 20
fold.

Additionally, the microvilli manifest small actin filaments that contract rhythmically to

increase the flow of intestinal contents around their respective microvilli, further increasing
exposure.
The enterocytes that line the villi in the small intestine are responsible for the absorption
of nutrition into the bloodstream.

Multiple peptidases (primarily amino- and dipeptidases)

protrude from the microvilli on the luminal membrane of enterocytes into the intestinal lumen,
where they digest larger polypeptides present in the intestinal contents. The remaining
tripeptides, dipeptides and single amino acids are transported into the cytosol of enterocytes,
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where the remaining peptides are digested into separate amino acids.

More than 99% of

proteins are digested into single amino acids.
Carbohydrates are digested in a similar manner into one of three types of sugars;
Glucose, Galactose, and Fructose.
Fat, due largely to its insolubility in water, has a different pathway. Bile acids and
lecithin from the liver, via the gall bladder, emulsify fat into small droplets before pancreatic
lipase splits the emulsified fat into fatty acids and monoglycerides. These are absorbed across
the ileum endothelium and sent to the liver via the hepatic portal vein.
The flow of nutrients is not limited to the digestion enzymes. Electrolytes, glucose and
single amino acids reach the blood via active transport through enterocytes. Water also flows
through enterocytes by osmosis, the rate of which is determined by the solute osmolarity
gradient.

Calcium, magnesium, and phosphate are actively absorbed directly into the

bloodstream as the regulation mechanism permits. Amino acids and glucose are also absorbed
by co-transport across the membranes of microvilli, with each glucose molecule or amino acid
requiring a sodium ion to be shuttled across the membrane along an electrochemical gradient.
This process happens in the microvillus membrane.
The colon has digestive and absorptive ability, but the digestive ability is primarily the
result of the colonic microbiome. The role of the colon centers around concentrating the liquid
intestinal contents from the small intestine into solid stool by absorbing electrolytes to drive the
osmosis of water from the stool into the blood. Nutrition absorption is limited to electrolytes and
water primarily (according to current knowledge). The epithelial cells of the large intestine
absorb electrolytes like sodium and chloride and any remaining water. Much of this absorption
is accompanied by the secretion of bicarb ions. Particulates remaining in the large intestine
may be further broken down by colon microbiota leading to the formation of Vitamin K, vitamin
B12, and gases (including methane). The remaining particulates and significant amount of
microbial flora are then excreted as feces.
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Waste system
Following the nutritional transfer, the remaining substance undergoes various reactions
in the large intestine before being expelled through the rectum. In the large intestine, any
protein that remains undigested undergoes anaerobic microbiota digestion through various
metabolic pathways and the large bacteria population present. Many of the excess proteins
undergo bacterial fermentation or become large fatty acids in the colon. Remaining amino acids
are metabolized by bacteria, which is required for colonic health.
metabolized material in the colon is excreted.

Any remaining non-
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CHAPTER 3: IMMUNE SYSTEM
Although the immune system consists of several different types of cells, according to
current knowledge, CD is primarily affected by the activity by T and B lymphocytes. Both cell
types start in the bone marrow as small lymphocytes developed from multipotent hematopoietic
CD34+ stem cells from which all blood cells develop. Approximately 30% of white blood cells
become small lymphocytes, a subset that “possess the ability to recognize and target
pathogenic microorganisms” (Murphy and Weaver, 2017). Lymphocytes with beginning T-Cell
Receptor(TCR) chains move to the thymus and become T-cells while the lymphocytes with
immunoglobulin(Ig) chains remain in the bone marrow and mature into naive B-cells.
B-cell Maturation
Small lymphocytes that remain in the bone marrow proceed through a series of
developmental stages to become B-cells. This process takes place largely attached to bone
marrow stromal cells in order to remain in close proximity to their paracrine secretions. Bone
marrow stromal cells secrete several compounds necessary for B-cell maturation including a
cytokine, Interleukin-7(IL7).

This starts following the expression of a B-lineage specific

transcription factor, E2A located in the germline DNA (sections of DNA coding for cellular
lineage development). Germline gene expression drives the transition of small lymphocytes into
the pro-B cell stage, and IL-7 released by nearby stromal cells promotes pro-B cell survival.
Initially, the pro-B-cell attaches to stromal cells in the endosteum. However, as the pro-B-cell
matures, it migrates through the trabecular space into the sinus of the marrow cavity while still
attached to stromal cells. Finally, the B-cell leaves the bone marrow to complete its maturation
in peripheral lymphoid organs.
One of the main distinctions found in small lymphocytes destined to become B-cells is
the beginning of an Immunoglobulin (Ig) chain. Immunoglobulin is a protein that acts as the
recognition site for a specific antigen:antibody combination presence. In this case, it activates
immunological processes within the B-cell. These Y shaped proteins consist of two types of
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protein chains referred to as Heavy chains and Light chains. Each B-cell Ig consist of two
identical hinged Heavy chains bonded at the hinge by disulfide bonds. At the V end of the Y,
the end of each heavy chain bonds with an identical light chain.

Figure 2: B-cell Immature Immunoglobulin(Murphy and Weaver, 2017)

The genes that code the Ig chains consist of three types of segments labeled
diversity(D),variable(V) and joining(J) gene segments and a fourth segment called the
constant(C) segment that is repeated in Heavy chains. In the germline, multiple variations of
these segments exist spaced apart. It is through random, somatic(inheritable) recombination
that diverse B-cells are produced in the body.
In the initial stage of B-cell development, the early-pro-B-cell rearranges DNA in the
germline to join D and J segments for the heavy chain for Ig later expressed on the cell surface.
At this point the recombinations occur in both alleles inherited from the parents. During this time
the cell is adhered to stromal cells in a signal that induces proliferation of the progenitors. Upon
the completion of the DJ rearrangement, the V segment is then rearranged to for a VDJ
segment through the same somatic process. During this phase, called the late pro-B-cell stage,
the rearrangement happens on one chromosome before the other. A successful rearrangement
halts further heavy chain rearrangement activity on the other chromosome. This heavy chain is
completed when RNA transcriptase rearranges the VDJ segment to connect with three C
segments before translating the genes into the polypeptide chain. This heavy chain is tested by
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creating a surrogate light chain for binding purposes. This complex signals the late pro-B-cell to
continue to the Pre-B-Cell phase.
Once the Heavy chain is arranged, it is transported to the cell surface during the Large
pre-B-Cell phase. This action inhibits further heavy chain rearrangement, thus creating allelic
exclusion by reducing the expression Recombination Activation Gene (RAG) and removing
access to the recombinase machinery. Following this, the cell undergoes several rounds of cell
division, creating a large population of smaller versions of the parent cell.
Next the small Pre-B-Cells begin light chain rearrangement.

The light chain is the

section of the immunoglobulin protein responsible for binding different antigen specificities, thus
light chain rearrangement occurs after successful heavy chain creation. Like the Heavy chain,
light chain rearrangement uses somatic recombination of several segments, in this case V, J
and C. This rearranging continues until a viable light chain is produced. The combination of the
2 sets of a heavy chain and a light chain yields an immunoglobulin called IgM (macroglobulin).
The final step for a immature B-cell prior to leaving the bone marrow is testing for
autoreactivity. The IgM is moved to the cell surface and tested against self-antigens. B-cells
that react to the self-antigen undergo either clonal deletion or receptor editing, that is, the genes
coding for the specific IgM return to the rearrangement state.
There are five main immunoglobulin expressed on B-cells that signify different reactions
by the B-cell.
IgM (macro globulin) is the first immunoglobulin expressed by B-cells. This class of
immunoglobulin only comprises 10% of those found in human plasma. When in serum, IgM
forms pentamers with low affinity but a high number of binding sites. This bloodborne structure
efficiently activates the complement system mostly in response to infection. In addition to the
antibody activity, IgM functions as part of B-cell‟s Antigen Presenting Cell (APC) activity,
displaying the protein component of the antigen as a Major Histocompatibility Complex (MHC)
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class II molecule.

IgM stimulation also initiates class switching to another type of

immunoglobulin on a B-Cell.
Another class of immunoglobulin is IgG (γ globulin) which has four monomeric
subclasses (IgG1-IgG4) and is the most abundant immunoglobulin in blood and extracellular
fluids. IgG specializes in broad reactions such as rapidly binding toxins to neutralize them. Like
IgM, IgG activates the complement system, another method of cellular neutralization. IgG binds
to Macrophages, Neutrophils, Eosinophils and, in some cases, B-cells, Langerhans cells,
platelets mast cells and NK cells and produces a needed response specific to each. These
cells then inhibit stimulation by the pathogen, induce death, or induce degranulation.
IgA (α globulin) can be dimeric or monomeric and is the primary immunoglobulin in
mucosal secretions. Current theory states IgA is responsible for protecting epithelial surfaces,
mostly in the gut, respiratory system, and exocrine glands by remaining in the mucin on the
surface until needed. IgA effectively binds bacteria, virus and toxins like IgG, preventing their
interaction with the epithelial cells it‟s protecting.

Also like IgG, IgA primarily works with

macrophages, eosinophils and neutrophils to induce killing.

Additionally, IgA regulates gut

microbiota. (Murphy and Weaver, 2017)
IgE is a monomeric immunoglobulin found in the bloodstream at low concentrations. It
has high affinity for mast cells and basophils and is predominantly responsible for the
autoimmune reaction called allergy. IgE also responds to multicellular parasites and mostly
activates a system of granulocyte degranulation
IgD is a more recently discovered immunoglobulin derived from the same RNA
sequence as IgM. It theoretically is involved in B-cell function cessation and seems to play a roll
in triggering cell activation and possibly apoptosis (programmed cell death).
A mature B-cell starts with IgM and then switches to a different immunoglobulin class
(IgG, IgA, IgE) using non homologous DNA recombination that mostly affect the C regions of the
immunoglobulin, a process referred to as class switching. Many times different cytokines affect
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class switching, often assisted by a T-cell that specializes in supporting this activity. Class
switching occurs when cytokines activate irreversible DNA recombination in the C region near
the J region of the antibody gene. Often the V region is actually preserved through this switch.
This does not hold true for IgM or IgD, as they are the initial antibodies expressed by a B-cell.
However, it does hold true for IgG, IgA and IgE.
Immunoglobulins can remain attached to their B-cells, in which case they are called Bcell receptors(BCR), or they can be secreted by specific B-cells and are called antibodies. Each
B-cell secretes antibodies with specificity for the same antigen already identified by the immune
system. Immunoglobulins bind antigens via specific binding sites. Immunoglobulin binding site
affinity for a particular antigen is determined generally by antigen size and shape and employs a
combination of noncovalent forces: electrostatic interactions, hydrophobic interactions, Van der
Walls forces, Hydrogen bonds or cation-pi interactions.
Antibodies‟ primary effects are to elicit an immune response that removes the antigen
and prevents further infection(like closing a cut). There are several mechanisms for this, such
as using the complement system to destroy the pathogen, activating other lymphocytes, or
inducing cytolysis. Different classes of antibody bind to different types of cells for different
functions.
Antibodies have a secondary effect of making an antigen ineffective. For example, a
virus may be designed to bind to a cell surface and then enter the cell for access to the cell‟s
DNA. However, certain antibodies will block this cellular binding.
T-cell maturation
The lymphocytes that enter the Thymus to mature into T-Cells are called thymocytes.
Like bone marrow stem cells, Thymocytes complete multiple stages of maturation to become Tcells. The stages, separated by changes to the cell surface and identified using flow cytometry,
consist of different expressions of cell markers such as CD4 and CD8. At different stages 6
markers (CD4, CD8, CD3, CD117, CD44 and CD25) are expressed or not expressed(referred to
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as positive or negative respectively).

During the initial stage, called thymic lymphoid

progenitors, CD117 and CD44 alone express positively. The thymocytes retain the ability to
develop into cells besides T-cells. Following the positive expression of CD25, the thymocyte,
now called pro-T-cell, is locked into becoming a T-cell. Next, early pre-T-cells follow a lack of
CD44 and CD117 expression.

This slows the proliferation of the cells and initiates T-cell

Receptor(TCR) rearrangement.
T-cell receptors(TCR) are antigen-recognizing membrane bound proteins that use
intracellular signalling complex to activate a T-cell.

Related to the immunoglobulins, this

receptor recognizes short peptides of an antigen bound in a MHC on antigen presenting cells
(this includes, but is not limited to B-cells, Dendritic Cells, and Macrophages). T-cell receptors
are divided into four different polypeptide chains; α, β, δ and γ. The most common, and most
studied pair are the α and β chains. Each of them have a variable region and constant region
with a cytoplasmic tail where the disulfide bond pairs the two into a heterodimer.

This

heterodimer is the αβTCR.
Once the pre-T-cell stage is reached, the TCR lineage commitment is in place to choose
between the αβ pair or γδ pair.

As CD44 decreases, the β chain gene locus undergoes

rearrangement. As with B-cells, the TCR chains have 3 gene segments; V, J, and D, which
undergo random somatic recombination before linking with the constant region in mRNA. For
an αβTCR dimer, the β chain begins this process as soon as CD25 expresses. The process for
Β chain completes as CD44 expression decreases.
degrades.

As this process completes, RAG-2

It halts the genetic recombination associated with β chain and ensuring allelic

exclusion, where only one allele remains expressed.

Any cell that does not complete this

process, fails to express the signal for the next step and undergoes apoptosis.
As the Β chain rearrangement is completed, CD25 expression ceases and the β chain is
partnered with a pre-T-cell receptor α and CD3.
rearrangement and promotes T-cell proliferation.

This completely arrests the β-chain
At this point CD4 and CD8 are both
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expressed. In general, thymocytes are categorized by the expression of these two
immunoglobulins. Prior to the expression of CD4 and CD8, thymocytes are referred to as
double negative. Once both are expressed, the thymocyte is termed double positive. The
majority of thymocytes in the thymus are double positive despite the short time the cells remain
in this state. During the double positive stage, the α chain, much like the light chain in B-cells,
rearranges the V and J segments to produce the α chain.

Unlike B-cells, where the

rearrangement of the light chain is halted as the immunoglobulin is assembled, the
rearrangement of the α chain only halts during the positive selection process. If the thymocyte
survives the selection process without successfully passing the positive selection test, the light
chain rearrangement will continue until either the cell passes the test or it is eliminated(Fig 3.).
The majority of mature αβ T-cells are classified by which of CD4 and CD8 they express
following their release into the body‟s systems.

CD4 and CD8 are coreceptor proteins

expressed by T-cells, and they are distinguished by Major Histocompatibility Complex (MHC)
recognition.

The MHC is a protein that binds and presents antigens to T-cells to initiate

activation of the immune system.

Structurally, these proteins differ widely, CD4 being a long

chain with four domains, and CD8 being disulfide linked dimer. Each of these immunoglobulins
bind with a different class of MHC complex, II and I respectively. This binding enhances the
TCRs receptivity to the MHC complex both by immobilizing the complex near a viable TCR and
by enhancing the avidity of the binding.
Double positive cells, cells that express both CD4 and CD8, undergo selection process.
This selection process organizes the cells into three categories; positive selection, negative
selection and non selected.

This process bases T-cell compatibility on reactivity to MHC.

During the positive selection process, thymic endothelial cells in the cortical node of the thymus
present MHC class I and II with a thymus-specific catalytic subunit to the newly arranged αβTCR. The proper arrangement receives the (positive) signal and activates the production of
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peptides required for continued existence and later differentiation.

Any cell that does not

complete this process is considered nonselective and undergoes apoptosis(Fig 3).

Figure 3: T-cell positive negative selection pathways

One of the peptides produced following the positive selection process, chemokine
receptor CCR7, is essential to the negative selection process. Following a migration to the
medulla of the thymus, thymic epithelial cells again present MHC to the T-cells, this time with
self-antigens. APCs, including dendritic cells and epithelial cells, separate T-cells that react to
self-antigens (the positive signal) and allow the remaining T-cells that do not react (the negative
signal) to continue to the next stage of development(Fig 3). Epithelial cells also check the
separated T-cells for the presence of Foxp3 on self-reacting T-cells. Such cells are spared and
become regulatory T cells, while the remaining auto-reactive T-cells not expressing FoxP3 are
deleted. Regulatory T-cells either develop in the thymus longer to control immune tolerance or
develop in peripheral tissue to control immunity during inflammation.
During positive selection, T-cells receive signals to produce certain peptides. These
signals, determined by the MHC to which the cell reacted, consist either of thymoproteasome
protease or a lysosomal protease. They drive expression of either CD8 or CD4 respectively,
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locking the T-cell into one lineage and determining one more stage of the maturation of that Tcell.
T-cells that leave the thymus expressing either CD4 or CD8 are considered naive Tcells. Naive T-cells represent only 5% of the thymocytes that enter the thymus from the bone
marrow. Ninety five percent of T cells that enter the thymus are killed at any of the various
stages of development.
The TCR, like its B-cell counterpart (BCR), recognizes antigens. However, unlike the
BCR, TCR requires that an MHC binds an antigen before the TCR can recognize it.. MHC
molecules are expressed on T-cells, B-cells, Macrophages, Dendritic cells and thymus epithelial
cells and are mostly divided into 2 classes, I and II. Both classes have a peptide binding groove
where antigentic peptides bind to the MHC molecule and are displayed on the surface of the
cells for recognition by TCRs. MHC class I binds shorter peptides (8-10 amino acids), and class
II binds longer chains.

Both have anchor residues in the polypeptide chain that bind and

stabilize the MHC molecule.
When an MHC:antigen complex on the surface of a cell is recognized by an appropriate
TCR on a T-cell, the presenting MCH molecule must also be bound by the appropriate
coreceptors on the T-cell for a response to occur.

CD4 recognizes MHC class II molecules

and CD8 recognizes MHC Class I molecules, allowing the form of the antigen to determine the
first layer of immune reaction.
B-cell and T-cell activation
T-cells and B-cells have specific locations they collect for activation of the adaptive
immune system, the white pulp of the spleen and the lymph nodes located throughout the body
and mucosal tissue. Naive T-cells migrate to the spleen and lymph nodes via the bloodstream
and take up residence in a particular node until they come into stable contact with a suitable
MHC:antigen complex inside one of these tissues on the surface of an APC. It is usually a
dendritic cell, though sometimes it can be a macrophage or B-cell. Antigen presenting cells, or
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APCs, are dendrites, macrophages and B-cells with an MHC expressed on their surface. The
MHC binds to a possible antigen and „presents‟ the bound antigen to a T-cell with the
associated CD4/CD8 ligand, thereby activating the adaptive immune response.
The activation of the immune system by TCR or BCR is considered the adaptive
immunity. The TCR, as stated, is a complex made of α and β chains surrounded by either CD4
or CD8 coreceptors.

The CD3 receptors also can assist in T-cell activation.

CD3 have

intercellular tails and assist the TCR and its signaling, particularly with the psi tail, which
transmits signals directly from the TCR to downstream cascades in the T-cell by
phosphorylation. This TCR activation starts a signalling cascade leading to transcription factor
activation, metabolism changes and integrin-mediated T-cell adhesion to the APC stabilized by
the formation of an actin cytoskeleton immune synapse.
Once activated, the CD4 T-cell undergoes clonal expansion and cellular proliferation
followed by differentiation into effector T-cells and memory T-cells. The effector T-cells have
three possible paths determined by cytokines expressed in their vicinity at key timepoints:
1.

migrate out of the tissue as helper cells and to the site of the infection,

2.

remain in the current location and interact with naive b-cells, or

3.

regulate the immune response by inhibiting future T-cell activation by

dendritic cells.
CD8 T-cells, once activated, become cytotoxic (killer T cells) and kill their target cells by
paracrine signaling and creating holes in them.
Co-stimulatory receptor binding is required for the activation of T-cells to provide a layer
of cell specificity and regulatory control. T-cells use CD28 which binds to ligand on the APC and
enhances the signal transmitted within the T-cells to allow for activation.

It also promotes

cellular proliferation, cytokine production and cellular survival. Regulatory molecules interfere
with costimulatory molecules to downregulate immune responses.
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T-cells that are not used by the B-cells have several different function once activated.
Helper T-cells that migrate to the site of infection could:
●

Opsonize macrophages or IgG isotypes for for phagocytosis

●

Work with IgE eosinophils, basophils and mast cells to target large

parasites
●

Opsonize neutrophils and IgG isotypes in response to fungi and bacteria

invaders.
Regulatory T-cells, designed to prevent autoreactive responses, develop from either
activate T-cells or directly from the Thymus. They suppress the proliferation and differentiation
of the helper T-cells listed above in addition to producing immunosuppressive cytokines and
suppressing inflammation. Memory T-cells are sent back throughout the body, to circulate to
allow for a quicker reaction to subsequent interaction with an antigen are sent through the tissue
with increased inflammatory chemokine receptors or are sent directly to various epithelial sites
to remain for a quick reaction at increased inflammatory sites. Memory T-cells also exhibit
cytokines that lengthen their lifespan past the normal few days.
Cytotoxic T-cells, produced from a T-cell with a TCR CD8 complex, target cells for
elimination.

This type of T-cell primarily limits the spread of damaged cells and infection

through cellular apoptosis. In general, Cytotoxic T-cells kill cells bearing specific antigen bound
to MHC class I. There is evidence that there are memory CD8 T-cells by using CD4 T-cells, but
this mechanism is not well understood.
The T-cells that assist the b-cells in the lymph tissue activate the B-cell function. This
activation is done by activating the BCR. The BCR, like the TCR, uses coreceptors, in this case
CD19, CD21 and CD81. CD21, part of the complement pathway, will bind certain fragments to
augment the signal of BCR. BCR activation also starts an integrin-mediated cell adhesion and
changes in cellular metabolism.

Instead of reforming the actin cytoskeleton, B-cells use
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signalling complexes on the cell-cell interface.

The costimulatory molecule for B-cells are

CD40.
If B-cell is the APC for the T-cell, its MHC class II presentation will bind with a CD4 Tcell. That will in turn drive the B-cell‟s differentiation into an antibody producing cell.
Once the BCR signal is received, the B-cell receives additional signals from the T-cell by
binding its own MHC class II complex with the T-cell‟s TCR complex. Then it undergoes isotype
switching described above. Once activation is complete, most of the B-cells proliferate and
differentiate into two types, plasmablasts, which synthesize antibodies, and plasma cells.
Plasmablasts secrete antibodies, but retain both surface immunoglobulin and MHC complex to
respond to further antigens. Plasma cells, on the other hand, produce and secrete antibodies,
but do not retain immunoglobulin on their surface. Thus they cannot undergo class switching or
react to further antigens.
The B-cells that do not complete the differentiation above will migrate with their helper Tcell to create a germinal center. While Plasmablasts produce more IgM antibodies since class
switch uses up time, the germinal centers undergo several processes of somatic hypermutation
and affinity maturation to produce the most effective antibodies followed by basic class
switching for different effector functions. These B-cells will eventually also be secreted either as
active B-cells or as memory B-cells.
Memory B-cells remain in the body, circulating until a secondary attack with the same
antigen triggers a response. Some of the memory B-cells will immediately begin releasing the
pre-optimized antibodies. A few of the memory B-cells will return to the lymph node to provide a
more optimized starting point for a germinal center and will undergo somatic hypermutation and
affinity maturation to further optimize the antibodies affinity for this antigen.
Other Immune cells
Dendritic cells are antigen presenting cells with additional immune functions including
transportation of toxins or pathogens, messenger cells, and cytokine expression.

In the

27
mucosal system, dendritic cells primarily transport pathogens across the epithelium and present
antigens to naive T-cells to initiate an adaptive immune response.
Macrophages are phagocytotic immune cells with two primary subtypes called M1 and
M2.

M1 is an inflammatory macrophage that activates bactericidal, inflammatory, and

phagocytotic pathways. M2 macrophage suppresses inflammatory function and activates repair
functions such as growth function.
γδ T-cells
When T-cell lineage commitment is decided, the alternative to αβ chain is the γδ chain.
Unlike the αβ chain, much less is known about the γδ TCRs. In humans, γδ TCRs are found on
a minority, only 5-15%, of T-cells. However, γδTCR expressing T cells have been found in all
vertebrates and represent half of the T cell population in mice. The majority of these γδT-cells
in humans are found during fetal and neonatal development. Past this stage of life, these TCells are located mostly in the mucosal systems and epithelial sites. Due to the similarities, γ
and β chain genes overlap and occasionally a γδ T-Cell will have an inactive β chain gene
already rearranged. Unlike the αβ dimer above, the γδ pair do not express CD4 or CD8 and do
not require MHC for antigen interactions. However, they do react to a special class of MHC
chains. Instead, γδ TCRs can target antigens directly, theoretically allowing them to create a
rapid response to antigentic stimuli by known stressors.

Many of the identified ligands for

γδTCRs such as endothelial protein C receptor, are found on cells undergoing stress or
damage. As γδT-cells can also trigger innate and adaptive immune response to antigens as well
as responding to them directly, γδ T Cells appear to function somewhere between the innate
and adaptive immune responses.
The second lineage T-cell, γ δ, is less understood that, its counterpart and is less prolific
in humans, except in the gut. Like αβ TCR, the TCR expressed on γδ binds peptides presented
by MHC molecules, specifically class Ib and nonclassical class I such as MICA or ULBP4.
However, a key difference is that γ δ T-cells recognize target antigens directly, allowing a more
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rapid response such as triggering locally at the site of an infection. These cells also respond to
unorthodox nucleotides and phospholipids. In the mucosal system they respond to α-gliadin by
killing the nearby stressed epithelial cells.
Mucosal system and immune system
The mucosal systems is comprised of the middle ear, the respiratory tract, the urogenital
tract, the gastrointestinal(GI) tract and the exocrine glands associated with these organs
(conjunctiva, mammary glands, salivary glands, lachrymal glands). To address CD specifically,
this discussion will focus only on the GI tract portion of the mucosal system.
Overview of mucosal system in digestive tract
The mucosal systems, so named for the mucus they secrete, constantly protect the body
from microbiota and other toxicants. The mucus secreted by gobleT-cells forms two layers, an
outer non-sterile layer that degrades microbes and an inner layer that contains a plethora of
antimicrobial molecules. This is further complicated by the microbiota that live in the gut and
perform important metabolic functions. These microbiota are capable of activating the immune
system. Such reaction would be aberrant and sometimes is known as an autoimmune condition
like Crohn‟s disease.
The mucosal immune system traditionally splits into two sections; effector and inductive
sites. The lamina propria and epithelium are the effector sites, and the Mucosa-Associated
Lymphoid Tissue (MALT) structures combined with mucosa-draining lymph nodes comprise the
inductor sites. These are so named by the process within the mucosa immunity they inhabit.
This division is not absolute given the variety of signals required.
Lamina Propria is a layer of loose connective tissue that lies between the basal layer of
the epithelium in the mucosal regions and forms the exterior of the intestinal tract and the
muscularis mucosae. Although this tissue is considered an effector site, antigens within the
tissue contribute to early T-cell and B-cell activity, such as differentiation and proliferation,
making it also an inductor site. For mucosal T-cells and B-cells, following travel through the
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lymph nodes and peripheral blood, antigen independent homing draw the cells to the mucosal
layers where lamina propria antigens contribute to retention, proliferation and differentiation. Tcells gains antigen homing due to priming in the lymph nodes.
The mucosal system has a thin layer of epithelium as a barrier defense. Most epithelial
cells in the intestine and other mucosal areas are highly polarized and connect to each other
using tight junctions to prevent the passage of molecules not chosen by specific cells or
paracellular pathways (passive water and solutes). One special type of cells in the endothelium
are the microfold cells(M cells). These cells are specialized epithelial cells characterized by
short or absent microvilli and the ability to take up antigens to deliver them via multiple
pathways through the epithelium to the adaptive immune system. They are located on the
surface of a Peyer‟s Patch.
The main function of the epithelium is to form a physical barrier while still allowing
nutrients to pass through, sometimes at tight junctions. Tight junctions are dynamic in form and
activity, typically excluding large molecules(stokes radius >11 Angstrom) and charge.
MALT collectively include mucosa-associated follicles and their larger aggregates.
These tissues originate the T-cells and B-cells traffic to the effector sites in additional to several
other common elements.

MALTs are divided into 3 groups by location; Nasal, Gut and

Bronchus, with the gut being the most studied. MALT tends to resemble lymph nodes in that
they have antigen presenting cells, interfollicular T-cells and B-cell follicles. However, there are
no afferent lymphatics and the structure lacks a capsule. Instead, MALT‟s antigen intake occurs
directly from mucosal surfaces using follicle-associated epithelium containing M cells which
deliver particulate matter, macromolecules and microorganisms across the epithelial barrier
using vesicular transport activity. Due to the shape of the M cells, T-cells, activated or memory
B-cells or Dendritic Cells will sit in the intraepithelial pocket to shorten the transcytotic pathway
and increase the speed of delivery. By definition, MALTs sample antigens directly from the
mucosal surface.
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MALT is also responsible for B-cell activation. In the gut, this is demonstrated by the
class switch from IgM to IgA in murine B-1 cells in the germinal center of M-cell pockets. B-cells
that retain their IgM antibody low affinity binds circulating antigens and activates the
complement system before relegating the antigen to remain for the memory B-cell function.
Research suggests IgM plays another yet unknown role in the induction of a secondary
response.
An important part of GALT (Gut-associated lymphatic tissue) is the Peyer's Patch which
is lymphoid tissue of the epithelium in the small intestine that contains M-cells, in addition to
follicle -associated epithelial cells. Unlike the remainder of the gut with microvilli, M-cells have
folded luminal surface that do not secrete digestive enzymes or mucins. This means Peyers
Patches also lack the mucus layer that covers the rest of the cells. It also contains the germinal
center in which B-cells are activated. In fact, have more B-cells than its lymph node counter
parts, and where T-cells and dendritic cells encounter antigens.

Peyer's Patches initiate

immune response in the gut.
In addition to the Peyer's Patch, the gut epithelium has intraepithelial lymphocytes
(IELs). More than 90% are T-cells, and around 70% are CD8 T-cells in the small intestine.
Although most have the appearance of activation, they seem to respond locally to a small
number of antigens by killing infected or stressed epithelial cells. Some IELs are γ δ T-cells.
These will also kill a stressed cell.
As stated earlier, the gut is lined with villi. In between these villi are areas called crypts
where undifferentiated progenitor cells reside. The lower sides of the crypts are stem cells that
can be differentiated into one of three cells for the villi: absorptive enterocytes, enteroendocrine
cells and goblet calls. The crypts regulate intestinal epithelial homeostasis. At the bottom of the
crypts below the stem cells are paneth cells which produce several immunologically important
molecules such as α defensin and certain antimicrobial peptides for the mucus layers.
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Cellular immune system
As with the rest of the immune system, a large part of the immunological reaction is
based on antigens. There are six pathways for antigens to cross the epithelial layer: M-cells,
dendritic

cells,

apoptosis-dependent

transfer,

goblet

cells,

macrophages,

immunoglobulin receptor (IgA) binding the antigen and traversing the barrier.

and

an

Epithelial cells

can perform autophagy and recruit neutrophils, macrophages or dendrites to destroy the
pathogen. M-cells, macrophages and dendritic cells will take up an antigen and transport it to a
dendritic cell on the other side waiting for the antigen. These macrophages are more populous
than in the rest of the body and rarely secrete inflammatory cytokines or reactive oxygen
species.

Instead. they focus on phagocytosis of pathogens or dying epithelial cells. The

apoptosis assisted transfer happens when an infected cell undergoes phagocytosis by a
dendritic cell, which then collects the antigen for use in activating the adaptive immune
response. Although the main function of the immune system is to react to pathogens, in the
mucosal immune system, the barrier stability takes a high priority and the immune reaction is
secondary.
The dendritic cells either in the germinal center of the Peyer's Patch or by direct
attachment obtain an antigen to present on the MHC for T-cells priming.

MHC II are

upregulated in the small intestine, thus initiating a pro-inflammatory response. MHC I and MHC
II are not alone in expression. They are joined by non-polymorphic MHC class I related
molecules. This allows TCR-α binding. It creates a primed T-cell. Primed T-cells include some
reaction to gut-homing cytokines, though some crossover among the mucosal system spreads
the reaction. This primed T-cell has the same choices as in the rest of the body, effector cells or
helper cells. Effectors cells produce cytokines as elsewhere, however a main function present
in mucosal T-cells is the preservation of the function and integrity of the epithelium.
Although all common types of B-cells can exist in the mucosal regions, certain classes
are far more common. Once a primed T-cell activates a B-cell in the Peyer's Patch, the B-cell
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undergoes class switching to IgA.

In the gut, IgA far exceed the normal plasma favorite IgG.

However, the reverse holds true in the tonsils (part of the bronchus mucosal system). Naive
lymphocytes remain in the Peyer's Patch until activation, at which point they migrate into the
mucosal lymph nodes to drain with the efferent into the thoracic duct. These then home in on
the lamina propria, binding specific B-cells. Thymus-expressed cytokines mediate the travel to
and retention of T-cells and B-cells in the lamina propria. The lamina propria contains many
immune cells that lack an immune response, including: mast cells, effector and memory CD4
and CD8 T-cells, macrophages, dendritic cells, innate lymphoid cells, and IgA producing plasma
cells. This combination displays many characteristics of a chronic inflamed tissue. However,
the actual inflammatory response is mitigated by an extreme amount of IL-10 produced by the
regulatory T-cells.
Unlike in the blood, IgA in the gut forms a dimer instead of a monomer. B-cell in the
mucosal regions tend to produce dimeric IgA exclusively, due to the helper T-cells in the gut. In
the lamina propria, B-cells activate as plasma cells and produce large quantities of IgA into the
subepithelial space. The IgA is then transported the rest of the way to the lumen by polymeric
immunoglobulin receptor in the epithelium, part of which cleaves and remains with the IgA to
protect it from proteolytic cleavage. This complex can bind toxins and either neutralize them
through inhibition or by using endosomes in the nearest epithelial cell.

Also the IgA can

transport the toxin across the epithelium, usually through a M-cell into a Peyer's Patch and
activate an anti-inflammatory response in a dendritic cell. This allows IgA to control microbe
penetration without damaging the epithelium with an immune reaction.
Tissue Transglutaminase
In CD there is a ubiquitous enzyme, not associated with the immune system directly, that
plays a large role in the pathology: Tissue Transglutaminase (tTG2). Tissue Transglutaminase
(tTG2) is a calcium-dependent enzyme primarily located in the GI tract.(Jabri and Sollid, 2006)
Tissue Transglutaminase belongs to a family of 9 transglutaminase. They are all distributed
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throughout the body performing various functions by forming Ca2+-dependent crosslinking
between lateral chains of glutamine and lysine residues for physiological purposes, often
modulating the immunogenicity of existing proteins. Oddly, for being enzymes, the majority of
the known transglutaminase functions are not enzymatic in nature; tTG2, for example, has
signalling and scaffolding functions independent of the catalytic activity.(Martucciello et al.,
2018)

Being both intracellular and extracellular, tTG2 is vital in stabilizing many proteins

including actin, myosin and spectrin, and in extracellular matrix used in wound healing and
signalling to macrophages for apoptosis. Theoretically, tTG2 is inactive in its extracellular state
until a RedOx reaction from stress activates it.

It also shows kinase, protein disulfide

isomerase, and deamidase activity in the presence of G-proteins, the latter of which is
responsible for the reaction in CD. (Martucciello et al., 2018)

Figure 4: Cellular functions of tTG2 both within and out a cell (Martucciello et al., 2018)
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When tTG2 encounters gliadin or a polypeptide of gliadin, it acts as a deamidase and
binds itself tightly to the polypeptide. This complex improves recognition by the antigen receptor
(HLA-DQ2/HLA-DQ8) presented to T-cells and activates the adaptive immune response in the
gut. B-Cells produce IgA tTG2 antibodies that serological tests detect in serum of CD patients.
These antigens can be detected in the basement layer of the intestines before the
morphological changes to the endothelium.(Martucciello et al., 2018) The presence of these
antibodies cause several immunological alterations such as enterocyte proliferation in the
intestines. Experiments seem unable to replicate these condition outside the body, suggesting
a celiac cellular environment still not understood. Indeed, skin-derived fibroblasts (cells not
directly associated with CD commonly) from a healthy patients respond to the anti-tTG2
protectively, whereas those of a CD patient do not in a way not understood. The antibody for
tTG2 is also responsible for several of the non-GI symptoms like dermatitis herpetiformis (type
3 transglutaminase) and some of the neuropathies(type 6 transglutaminase). (Martucciello et
al., 2018; Stenman et al., 2008)
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CAPTER 4: CELIAC PATHOPHYSIOLOGY
Gluten
Gluten is the name given to water insoluble protein present in cereals in the Triticeae
tribe of the Pooideae subfamily of grasses which includes Wheat, Rye, Barley, and Spelt. The
presence of this protein confers certain properties on wheat utilized in cooking such as
elasticity, viscosity, cohesivity and a certain absorption of water. From a biological standpoint,
gluten is a protein in the wheat germ meant to support seed germination and feed young
seedlings. Gluten proteins contribute to the rheological properties of hydrated wheat, mainly
due to being prolamin or rich in proline/glutamine sequences. Wheat gluten is divided into two
categories, gliadin and glutenin. The alcohol soluble gliadins consist of homologue monomeric
proteins and contribute to the elasticity, specifically extensibility, and viscosity properties of
hydrated wheat. Glutenin is the non-alcohol soluble fraction and consists of aggregate proteins
bonded by disulfide bonds between cysteines. It contributes elasticity and strength. In rye and
barley, gluten contains hordeins and secalins, respectively, instead of gliadins. Due to the
similarity in response and form, gluten refers to proteins in barley, rye, kamut, durum, emmer,
spelt and triticale(wheat) groups. Closely related groups, such as oats have proteins that can
elicit the same response as gluten in some cases.(Balakireva and Zamyatnin, 2016; Fric et al.,
2011; Londono et al., 2013; Tapsas et al., 2014; Valenti et al., 2017)
Gliadin is composed of several isoforms based on the electrophoretic activity; α, β
omega and upsilon. The gliadin that triggers an adaptive immune response is the α-gliadin.
Gluten Digestion
Gliadin can be broken into many smaller peptide chains. Five of these are repeatedly
implicated in CD; 33-mer, 26-mer, 20-mer, 19-mer and 13-mer. The 33-mer and 26-mer are
immunogenic, that is they activate the adaptive immune system. The 20-mer activates the
zonulin pathway which opens tight junctions in the endothelium. The 19-mer and 13-mer are
toxic and activate the innate immune response.

Assuming the innate immune response
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happens enough times, or continues for long enough, a second adaptive immune response will
occur. This happens when these peptides interact with the immune system, primarily after they
have crossed the epithelial barrier into a Peyer‟s Patch, or lamina propria.(Caminero et al.,
2014)
The breakdown of gluten begins in the saliva.

Due to the high content of Proline-

Glutamine residues in the mouth, glutamine endoproteasic activity preferentially cleaves basic
proline rich proteins predominantly when the proline is bracketed by glutamine and any other
residue. This is necessary for the normal environment of the mouth and is possibly microbial in
origin. Additionally, further study noted that the immunogenic peptides(33-mer and 26-mer) that
later cause CD issues can be thoroughly degraded by the oral protease. Additionally, several
oral micro-organisms have shown remarkable ability to digest gluten.

Suspended bacteria

found in plaque(Rothia aeria) can degrade gliadin by 50% in 30 minutes.

Others could

participate in gluten digestion: Streptococcus mitis and Bifidobacterium dentium, for example.
There is some evidence that these microorganisms could survive the stomach to continue
digestion in the intestine.(Caminero et al., 2014; Tian et al., 2017)
Additional research has shown that the changes gluten undergoes during the baking
process inhibits the salivary amylase from digesting the protein.

In fact, it decreased the

digestion to the point that even with amylase added to the duodenum digestion site,
immunoreactive polypeptides persisted. Simulated digestions, at several levels of enzymes,
showed these polypeptides remained up to 2 hours later.(Smith et al., 2015)
Like other proteins, pepsin attacks gluten components once in the stomach. Current in
vitro studies show that the pepsins in the stomach only partially proteolyzed gluten proteins.
Like many proteins, gliadin has a buffering effect on HCl, in this case at pH of 3.0.
Research conducted at this pH shows that gliadin forms several oligomers that collect in nonspherical aggregates. These elliptical oligomers were studied at varying concentrations at pH of
3.0 showing the supramolecule forms elongated aggregates of varying size. This is backed by
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ab initio calculations that show that two highly hydrophobic sites prone to aggregation are
exposed in this stable form.

This explains the proteolytic resistance the gliadin had and

suggests that the immunological response is indicative of a real trigger instead of a random
occurrence among gliadins (the full sequence of α gliadin was reported).(Herrera et al., 2018a;
Herrera et al., 2018b)
In CD, the damage happens in the small intestine, however much of the final digestion of
gluten and gliadin appears to happen in the large intestine via microbiota. A study recently
found certain microbiotica in the small intestine of CD patients that was not present in healthy
individuals. This leads to the conclusion that duodenal bacteria much like those in the large
intestine can hydrolyze the longer chains. This is further supported by the increase in bacterial
metabolism in the colon in healthy patients when their gluten intake increases. Additionally,
even the earliest diagnosis of CD noted the difference in the presence of fatty acids in the
patient‟s feces, denoting a change in bacteria population in CD patients. Since this doesn‟t
change during GFD, it is likely part of the cause of CD‟s symptom and not another symptom in
and of itself.
LIke other proteins, gluten interacts with various enzymes from the pancreas as the
polypeptide enters the small intestine. Many studies show that gluten resists digestion, likely
due to the high proline content (estimates 15%-25%). The additional proteolytic activity by the
brush border has little discernible effect on the gluten proteins despite the presence of enzymes
that cleave proline bonds. Some polypeptides have minor cleavages, but the polypeptides
responsible for the CD immunoreaction, such as the 33-mer, do not appear affected. Likewise,
several enzymes in the brush border of the small intestine can cleave proline and glutamine
bonds, but have little effect on the 33-mer. The bacteria in the duodenum does not appear to
hydrolyze gliadin sufficiently to facilitate absorption in the small intestine.(Caminero et al., 2014)
In the large intestine, although there are bacteria that could affect the long peptides,
studies show that the majority of the gluten we ingest ends up excreted as feces. Since this is
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proportional to the amount of gluten ingested, several gluten peptides must be resistant to
human and bacterial digestion In both a healthy and CD patient, the loss of gluten decreases
the diversity and population of Lactobacillus and Bifidobacterium species.

Other forms of

microbiota increase, such as Enterobacteria, and fecal glutenasic activity increases Even the
endoproteasic activity seen in the saliva can be detected in the feces.(Caminero et al., 2014)
Some studies have show the importance of bifidobacteria in the large intestine in the
digestion of gliadin.

Certain strains cleaved the long chain protein into cytotoxic peptides,

however B longum CECT 7347 hydrolyzed even the 33-mer into non-cytotoxic peptide chains.
Furthermore Bacteriodis fragilis demonstrated similar activity along with several strains in the
Firmicutues and Actinobacteria phyla that already exist in the large intestine.
In an attempt to further understand activity that breaks down gluten/gliadin, studies into
human feces measured enzymatic activity on healthy and CD patients with and without gluten.
Feces glutenase activity present in patients showed hydrolytic activity against gliadin
compounds such as 13-mers, 19-mers and 33-mers.

Even with this activity, the peptide

resisted degradation in excess of 60 minutes. The attempt to identify the proteins responsible
for the fecal glutinase activity indicated two proteins with a high homology to human elastase
3B(CEL3B), 1 with human elastase 2A(CEL2A), and 1 with human carboxypeptidase
A1(CBPA1). Further testing with a similar, commercially available mix showed hydrolytic activity
in the presence of gliadin and gluten. Since the immunological reaction is actually prompted by
certain immunogenic mimics, specifically 13-mer, 19-mer, and 33-mer, the hydrolytic activity of
these proteins were tested as well. The 13-mer and 19-mer both degraded during a 60 minute
incubation in either CEL2A and CBPA1, but CEL3B seemed ineffective at this digestion. The
19-mer did leave some smaller peptides. However, in 60 minutes and even in 24 hours, the 33mer failed to digest more than 66% in any of the identified proteins. Patients with CD showed a
significant increase in the ability to digest 33-mers over those without. Further study comparing
patients with and without CD to those related to patients with CD showed that this activity was
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higher in patients with confirmed CD than with healthy patients by 171-466%(Gutierrez et al.,
2017). Furthermore, this difference persisted even when the patient was on a gluten free diet.
The combination of proteins that supported feces glutinase activity was such that in CD patients,
all the 13-mer and 19-mers successfully degraded, leaving only the 33-mers. This research,
combined with earlier research, shows that only 30% of the immunogenic compounds survive
digestion in vitro and no bacteria with glutinasic activity survive in the feces.(Caminero et al.,
2015; Gutierrez et al., 2017)
Immune Reaction to Gluten
Currently, it is unknown what causes the activation of CD within an individual. There are
genetic markers that show a strong statistcal correlation to the onset of CD.

Additionally,

“Breastfeeding and the timing of gluten introduction in the diet, viral infections that promote the
secretion of interferonα and smoking are some of the factors that appear to influence the
development of the disease”(Green et al., 2005).(Monteleone et al., 2001; Stenlund et al., 2002;
Vazquez et al., 2001) Some research indicates the trigger could be a rotavirius protein (VP7)
that mimics tTG2 peptides or T1L/T3D-RV that establishes an environment that allows gliadin
peptides to activate the immune system.(Brown et al., 2018; Volta et al., 2013)

Further

research indicated a bacterial infection could trigger CD, either by the bacteria population
directly or by the loss of commensal bacteria due to antibiotics(Fig 5).(Chander et al., 2018)
However, at this time the triggers remain elusive.
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Figure 5: Viral trigger for CD – Either the bacteria or antibiotics produce an environment that allows CD to
start.(Chander et al., 2018)

Current studies divide Celiac Disease into several types; symptomatic, asymptomatic,
latent and potential. Symptomatic CD is the most studied and most diagnosed, as patients with
this form experience noticeable effects of ingesting gluten. However, only 50% of CD patients
fall into this category. Asymptomatic CD, or silent CD, involves the presence of genetic and
antibody markers and positive biopsy finding, but lacks overt symptoms such as dermatitis
herpetiformis and gluten ataxia. Often this is diagnosed when the more dangerous symptoms
associated with nutrition deficiency become apparent. Latent CD is the condition where the
entreopathalogical side of CD is not constant. The final category of CD is Potential CD defined
as the presence of the antibodies with the complete lack of enteropathy. Latent and Potential
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CD could show symptoms and are rarely diagnosed.

Patients with potential CD remain a

medical concern. The lack of lesions or villus atrophy imply that the presence of the antibodies
is not causing harm. However, in a study done in 2010 on children, 30% of verified Potential
CD patients developed active CD with lesions within 3 years.

However, since 14% of

participants lost the antibodies in their serum completely, the risks associated with Potential CD
remain inconclusive. The potentials studied showed the same increase in B-cell and T-cell
activity characterized by CD.

However, there was marked increase in IL-10, inhibitory NK

receptors and IEL that lacked the killer phenotype, suggesting the presence of an immune
response in a lower magnitude.(Troncone and Jabri, 2011)
T-cells
The initial reaction to CD appears to happen in the Duodenum of the small intestine
where cytotoxic polypeptides from gliadin interact with IELs in the endothelium and
immunogenic polypeptides interact with the adaptive immune system.

The cytotoxic

polypeptides, principally 13 and 19-mers, interact with cytotoxic T-cells (expressing CD8) to
activate various innate immune responses. The expression of gluten-specific CD8 T-cells refers
to stress induced signals and the TCR binding to MHC class 1 chains A and B and HLA E
mostly. This is an antigen-nonspecific reaction and it is assumed that the peptide is mimicking
another peptide, one which is actually toxic.

Natural Killer receptors, upregulated by IL15, on

IEL receive the signal from these compounds to activate kinase that should mediate T-cell
activity. Instead, the NK receptors seem to attack the epithelial cells in the lining of the lamina,
allowing more of the toxic peptides to cross the barrier. Concurrently, the predominant inhibitory
NK receptor is down regulated allowing cytolysis. This creates a T-Cell environment with no
specificity, that is able to kill cells, secrete cytokines and proliferate upon receiving stress or
damage signal from the surrounding cells.(Garnier-Lengline et al., 2015; Jabri and Sollid, 2006;
Menard et al., 2012; Murphy and Weaver, 2017; Smith et al., 2013)
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Figure 6: Overview of Gluten peptides interacting with mucosal immune system (Balakireva and Zamyatnin,
2016)

The addition of gluten in the system increases a substance called zonulin, which
regulates the tight junctions in the endothelium. The current theory is that zonulin released by
mucosa in the presence of gluten, specifically 2 different 20-mer polypeptides cleaved from
gliadin, increases paracellular permeability and stimulates transcytosis in the small intestine by
producing an “adjuvant effect exerted by zonula occludens toxin, its analogue, on antigen
specific IgA promoting] IgA-dependent transcytosis of gliadin peptides”(Menard et al., 2012).
(Fasano, 2012; Menard et al., 2012)

Furthermore, this interaction with zonulin occurs

exclusively on the luminal side of the endothelium, utilizing the chemokine receptor CXCR3 and
adapter protein MyD88 to release zonulin into the intestine. Zonulin release is also heavily
associated with Type 1 Diabetes. This gliadin peptide transcytosis leads to damage of the
epithelial tight junctions allowing the partially digested gliadin fragments, specifically the 26-mer,
33-mer, 19-mer and 13-mers, to enter the bloodstream and interact with the T-Cells
there.(Fasano, 2011, 2012; Jabri and Sollid, 2006)
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While the innate reaction continues, the adaptive immune reaction begins, either as a
result of the innate immune response or as a response to immunogenic polypeptides,
specifically 26 and 33-mers, crossing the endothelium.

These polypeptides cross the

endothelium border in some fashion to interact with tTG2 already present. Gluten peptides are
presented to T-cells using the HLA on APCs. HLA-DQ2 and HLA DQ8 have unique binding
sites that accomodate the amino acid chains in the 33-mer and 19-mer chains left from glutenin.
The preference in these binding sites weighs heavily negative charged anchor residues (HLADQ2 at positions P4, P6, or P7,31,32 and HLA-DQ8 at positions P1 or P9(Jabri and Sollid,
2006)) which are introduced to the gliadin residues when TG2 converts glutamine to glutamic
acid. The 33-mer of α-gliadin is especially susceptible to this conversion and resists digestion
otherwise due to high proline count. Due to its binding motifs, this chain stimulated T-cells by
targeting 3 different epitopes. As a point of interest, avenin in oats contain some of these
sequences for T-cell epitopes provided they avoid digestion.
Once activated, some T-cells differentiate into helper cells and activate B-cells, and
some become effector cells that start an advanced healing response. This induces an M2phenotype response in activated macrophages in the GI tract, thus decreasing the inflammatory
response and increasing cellular healing cytokine activity and cellular proliferation. The zonulin
pathway reaction induces several pro-inflammatory responses, so this is a counter-reaction
happening in the same area.(Barilli et al., 2018; du Pre and Sollid, 2015; Nikulina et al., 2004)
Concurrent to this T-cell reaction, the crypt cell division increases to develop into overt
lesions in between villi, bringing the villi surface closer together. The proliferation of CD8 T-cells
kills endothelium cells, and the adaptive immune reaction generates inflammation which results
in gaps in endothelium.

The adaptive immune system also generates a large increase in

plasma cells generating IgA antibodies in the lesions developing in the endothelium and
increases the M2 macrophages which promotes cellular healing.(Barilli et al., 2018) When
these gaps heal, the resultant bridge to the nearby damaged villi results in villous blunting. One
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study showed CD patients with villi average height of 86 um, one sixth the height of a healthy
patient(Vuoristo, 1987). Indeed, both the crypt hyperplasia and T-cell lymphoma is not reported
in other inflammatory enterocyte diseases at this time.(Smith et al., 2013) This decrease in
viable endothelium surface area results in nutritional deficiency.
Following a GFD, CD8 T-cell population return to normal. However, the γ δ T-cells with
the Vδ1 gene segment population remains heightened for a prolonged time. (Murphy and
Weaver, 2017; Smith et al., 2013)
Symptoms
Most of the physiological conditions related to CD are separated into two categories:
symptoms related to the damage in the GI tract and symptoms that are directly related to the
gluten interaction with tTG. The second set belong to the diagnosis of Symptomatic CD and are
considered most severe, as well as most recognizable.
Asymptomatic or Silent CD is harder to diagnosis due to the lack of clearly discernible
symptoms.

These patients usually report a collection of symptoms, usually GI or nutrition

related, that persist until a GFD is initiated. Table 1 lists the common symptoms for silent CD.
(Green et al., 2005; Jericho and Guandalini, 2018)
Table 1: Symptoms of Silent Celiac Disease (Green et al., 2005)

Children

Adults

Short Stature
anemia
neurological symptoms
Dermatitis Herpiformis
Anemia
Reduced Bone Density
Apthous Stomatitis
Dental enamel defects
Infertility
recurrent miscarriages
IBS
Dyspepsia
Esophageal reflux
neurological symptoms
Autoimmune Diseases
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The majority of the nutrition deficiency is due to the damage to the villi in the small
intestine, making this the best sure diagnosis currently. Since the complex cooperation of the
villi system increase the active surface area of the small intestine by 1000 fold, this loss
significantly undermines the body‟s ability to collect nutrition. This systemic atrophy is usually
noticed when the patient achieves extensive damage resulting in hospitalization, sometimes
multiple times before accurately diagnosed and treated.(Jericho and Guandalini, 2018;
Marginean et al., 2018; Murphy and Weaver, 2017; Smith et al., 2013)
Since one of the earliest known signs of Celiac is the greasy feces, the function of the
gall bladder, liver and biliary system contribute to a common symptom. The villous atrophy in
the duodenum hampers the secretion of a hormone, cholecystokinin, which promotes
gallbladder motility and interacts with several nervous pathways including satiation. Studies in
the 60s measured a deficiency in pancreozymin, renamed to cholecystokinin later, and a follow
up study in 1971 showed that the gall bladder in untreated CD patients‟ gallbladder failed to
contract in the presence of a high fat diet unless stimulated directly with cholecystokinin.(LowBeer, 1971) Further research into the bile salts and taurocholate pools demonstrated that while
the ratio of cholate to chenodeoxycholate skewed slightly toward cholate, the big difference
between a healthy patient and untreated CD patient was the size of both pools, each being
nearly 3 fold greater. Since the turnover rate remained, the size is likely due to the lack of
gallbladder stimulation resulting in failure to release bile salts into the small intestine. This lower
concentration of bile salts would fail to inhibit hepatic bile salt production, thus increasing the
total bile salt pool and making bile salt sequestering a possible symptom in CD.
The ileum environment contributes to the resultant steatorrhoea. In certain cases of CD,
the ileum attempts to compensate for the decreased absorption in the duodenum and jejunum.
The ileum‟s ability to sustain this hyperactivity determines the severity and variety of many of
the apparent GI symptoms. Failure of the ileum to handle the bile salts, whether through direct
CD damage or through indirect damage while supporting the damaged duodenum and jejunem,
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often results in the steatorrhoea historically indicative of CD.(Gillberg, 1980) Physiologically,
when the bile salts unabsorbed enter the colon and the high fatty acid count due to incomplete
digestion reach the large intestines, they actively induce water and electrolyte secretion. Not
only would this exacerbate nutritional deficiency, but it shows in the feces, doubling the dry
weight, tripling the water weight and quintupling the fat weight of a healthy patient.(Vuoristo,
1987) After 8 months of GFD, the feces weight normalizes by half, showing a partial recovery
and leading to the recommendation of 18 months on GFD prior to recovery verification.(LowBeer, 1971; Low-Beer et al., 1973; Vuoristo, 1987)
The liver, an integral part of the biliary system, is also affected by CD. While there are
many liver malfunctions, the two most associated with CD are cryptogenic disorders and
autoimmune disorders. In half of untreated CD patients, the liver had increased transaminase
averaging 61 for ALT and 47 for AST, indicating liver distress but not elevated enough to cause
alarm during testing. Often, if left untreated, this is followed by chronic active hepatitis or
primary biliary cirrhosis.(Duggan and Duggan, 2005) Chronic Active Hepatitis is a repeated liver
infection, in CD likely due to the combination of the increased intestinal permeability and the
transfer of immunologically active molecules and cells through portal circulation.(Anania et al.,
2015) Primary biliary cirrhosis(PBC) or the progressive breakdown of hepatic biliary ducts, is
often the result of antimitochondrial antibodies and autoreactive T-cells. It generally ends with
liver failure. Between the gallbladder status and the immune connection, numerous studies
show a high correlation between CD and PBC.

Additionally, the increased intestinal

permeability in CD could allow the gut microbiota access to the liver leading to a possible PBC
trigger, certain gram-negative bacteria molecular mimics. It is recommended that patients with
one condition get tested for the other.(Volta et al., 2013) Most of these chronic liver conditions
improve dramatically on a GFD.(Anania et al., 2015; Casella et al., 2013; Choung and Murray,
2017; Duggan and Duggan, 2005; Lo Iacono et al., 2005; Majumdar et al., 2018; SzaflarskaPopławska, 2011)
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Bone health in CD patients is complicated. Various bone-related conditions including
low bone mass, osteoporosis, secondary hyperparathyroidism, and osteomalacia are reported
in conjunction with CD.

Some of this degeneration is due to the decrease in nutritional

absorption by direct loss of calcium and vitamin D. However, in CD, the loss of calcium triggers
an increase of parathyroid hormone that stimulates osteoclast mediated degradation, often
leading to osteoporosis and osteopenia. Additionally, in males, the lack of nutrition often results
in hypogonadism, which can have a significant impact on bone growth. Indeed, those with
untreated CD had a prevalence of low bone density between 38% and 72%, and, conversely,
the osteoporotic population‟s prevalence for CD is triple that of the general population. The lack
of nutrition is not the only factor in low bone demsity in CD patients as the prevalence of low
bone density in CD patients with GFD remains between 9% and 47%. The release of certain
immunological proinflammatory cytokines during the autoimmune reaction increases the
osteoclast activity. Theoretically, the immune reaction to tTG2 causes the release of these
proinflammatory cytokines which supports osteoclast activity. (Duggan and Duggan, 2005;
Zanchetta et al., 2016)
One of the common visual symptoms of CD is dermatitis herpetiformis. This blistering
skin disorder occurs when an immune response to gliadin deposits IgA Anti-tTG2 and Antitransglutaminase 3 in the epidermis correlated to the degree of enteropathy. Another common,
but less predictive symptom is gluten ataxia, where the patient loses muscular control for a short
time possibly due to the expression of antibody to TG6, an isozyme in the brain.

Other

neuropathic conditions related to gluten have been discovered, however for gluten ataxia, only a
third showed evidence of enteropathy.(Troncone and Jabri, 2011)
Approximately 10% of CD patients suffer from some form of neurological symptoms, with
ataxia and peripheral neuropathy being the most common. Even lacking overt neurological
symptoms, a study showed untreated CD patients had changes to cortical gray-matter and
caudate nuclei related to duration of gluten ingestion.(Bilgic et al., 2013) Ataxia, or the
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temporary loss of function in motor muscles, can start as simple unsteadiness in stance and
limbs. A factor in these neuropathies is anti-transglutaminase 6, a relative of tTG2, which also
appears in untreated CD patients and is involved in gluten-dependent ataxia.(De Leo et al.,
2018) Frequently, ataxia continues to cause several other issues, including myoclonus and
cerebellar atrophy. Autopsies of these patients show atrophy, gliosis, Purkinje cell loss and
degeneration of the posterior columns of the spinal cord.(Green et al., 2005) Peripheral
neuropathy is another frequently associated with CD. In fact, one study showed that 5% of
patients with peripheral neuropathy likely also have CD. Certain Epilepsy patients are also CD
positive, and there is a suspected causal relationship since the cerebral calcifications were
traced back to the same HLA-phenotype, even in non-CD patients. Additional neurological
symptoms associated with CD are mood disorders, such as depression and anxiety,
neuromuscular disorders, such as myositis, movement disorders, such as Huntington‟s disease,
and cerebral abnormalities, such as cerebral vasculitis. CD screening for a patient with Down
Syndrome has nearly become the norm. Many of these are attributed to anti-gangliosides as a
result of CD.(Green et al., 2005) Another factor called Brain-deprived Neurotropic Factor
(BDNF), a protective protein in the central neural system responsible for neuronal plasticity,
specifically during stress and linked with mood disorders, was linked to intestinal inflammation
including CD. This serological concentration remained increased even following a GFD. CD
neurolopathology also includes depression, anxiety, apathy, irritability, migraines, and epilepsy.
(Campagna et al., 2017; Luostarinen et al., 2003; Margoni et al., 2018; McKeon et al., 2014;
Pengiran Tengah et al., 2002; Pennisi et al., 2017; Wills, 2000)
Table 2: Common Neurological Symptoms of CD (Green et al., 2005)

Peripheral neuropathy
Ataxia
Stiff-man syndrome
Cerebral vasculitis
Anxiety/depression
Huntington’s disease
Dementia

Headache w/ white matter abnormalities
Epilepsy/cerebral calcifications
Brainstem encephalitis
Progressive multifocal leukoencephalopathy
Progressive myoclonic encephalopathy
Schizophreniform disorder
Inclusion body myositis

Chorea
Neuromyotonia
Epilepsy
Myoclonus
Polymyositis
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Both individual studies and a 2015 meta analysis showed no statistical correlation
between circulatory conditions and CD: including cerebrovascular disease, coronary heart
disease, stroke or brain hemorroage(Bardella et al., 2004; Heikkila et al., 2015) Where many
autoimmune conditions seem to have cardiovascular complications, CD does not appear to be
one of them.(Bardella et al., 2004)
Studies show women with untreated CD have three times greater tendency than normal
to give birth to infants with low birth weight and intrauterine growth retardation. This is likely
largely due to the the decrease in nutrition available to the fetus during gestation.(Norgard et al.,
1999)
Other Gluten Sensitivities
Wheat allergy: CD differs from wheat allergy in basic immunological response. Like
most conditions termed allergies, wheat allergy involves a immunoglobulin IgE reaction on a Bcell to produce a well documented immune response including inflammation, vasodilation and
resource redistribution(Troncone and Jabri, 2011). Wheat allergy has a prevalence of 0.5% in
the general population. Unlike CD, which reacts to water-insoluble prolamins, wheat allergy
reacts with water soluble proteins. Thus, only wheat need be avoided, not necessarily rye, spelt
or barley. Many with wheat allergies acquire it through a combination of exposure and exercise.
In other words, most wheat allergies are exercise induced, meaning they only cause asthma,
urticaria, or anaphylaxis when the ingestions of the food combines with exercise in close
succession. Currently, omega-5 gliadin is the theoretical cuprit. Another condition referred to
as Baker‟s Asthma results in arthritis and asthma from inhaling flour particles. In this case,
individuals can ingest the wheat, but need to avoid breathing it in. As with other allergies, a skin
test is the common diagnosis test. Unfortunately it has a high false negative rate. As with most
IgE reactions, the condition resolves itself when the allergen is eliminated from the system. This
particular allergy is predominantly in children and normally disappears as the child grows. This
is in direct contrast to CD where the reaction can continue for some time after, and the damage
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is less reversible.(Balakireva and Zamyatnin, 2016; Burkhardt et al., 2018; Elli et al., 2015;
Henggeler et al., 2017)
The presence of IgD antibodies in gluten reactive situations was studied and shown to
be elevated, but no explanation has been discovered or researched(Burkhardt et al., 2018).
Double blind challenge evidence for gluten sensitivity is weak with the exception of
wheat allergies. The proliferation of the gluten free diet seems mostly media based. However,
since the subjective improvement in the patients‟ lives can be substantial, the term Non-Celiac
Gluten Sensitivity(NCGS) is used. This condition, however, is poorly defined and highly variable
from one patient to another. Some symptoms of gluten ingestion are internal, such as stomach
ache, and some are external, such as skin rashes. Additionally, some research found that
certain conditions improved with the removal of Gluten from the diet, such as schizophrenia,
bipolar fibromyalgia, and spondyloarthritis. Further research demonstrated that certain NCGS
patients benefit from enzyme replacement therapy, indicating a reaction to undigested gluten
which is divergent from CD pathology.(Ido et al., 2018) Due to the lack of biomarkers and
widely variable reactions, NCGS remains difficult, if not impossible, to diagnose outside of the
process of elimination at this time.(Burkhardt et al., 2018; Hadjivassiliou et al., 2016; Henggeler
et al., 2017; Valenti et al., 2017)
Other misdiagnosis: There are several conditions which overlap with CD and other
gluten related immune reactions. Irritable Bowel Syndrome(IBS) is one such condition. Due to
the damage in the intestine during IBS, it is plausible that many patients with IBS are CD
positive and undiagnosed or misdiagnosed as IBS. Furthermore, if the patient is diarrheapredominant, the recommendation of CD screening is logical. The symptoms for IBS include
abdominal pain, gas, mucus in feces and diarrhea/constipation, which match many symptoms
for CD. This implies that should the IBS symptoms increase with gluten intake, the presence of
CD is likely.(Troncone and Jabri, 2011)
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In addition to other gluten sensitivities, there are a number of conditions that can mimic
CD. IBS, as demonstrated above, overlaps in symptoms. Small intestine bacterial overgrowth,
inflammatory bowl disease, microscopic colitis and issues in the thyroid and adrenal system all
show clinical features similar to active CD. Crohn‟s in particular, mimic‟s CD in patients. Since
the cause and diagnosis standard for both diseases remains under debate, separating the two
medically is complicated. (Kamboj and Oxentenko, 2017)
Treatment
The only existing treatment for CD is adopting a strict gluten free diet, which is difficult
and expensive to maintain. Meals, in addition to providing nutrition, are often central to family
and social gatherings, to business meetings, and networking and work functions. This makes
adhering to a strict gluten free diet socially challenging and even a career hindrance for some.
Finding gluten free food items has become easier as the number of non-Celiac consumers on
gluten free diets have created a larger market for gluten free foods, which have expanded in
variety and availability in recent years.(Naqash et al., 2017) However, gluten free items are still
not ubiquitous at supermarkets and their cost is often significantly higher than comparable
products made with gluten, adding cost as another drawback to a gluten free diet. Wheat flour
is commonly used as a binding agent in medications, and even typically gluten free medications
may have batches that are not gluten free when their manufacturer uses a different flour blend
for cost or availability reasons, limiting medication options for CD patients. Yet another issue
involves assessing the integrity of “gluten free” labeling on meals at restaurants and even in
prepackaged foods. For Celiac patients, preparation of their gluten free meal using the same
knife, cutting board or pan used to prepare foods with gluten can provide enough cross
contamination to trigger intestinal inflammation, making it very difficult to eat strictly gluten free
at restaurants.(Young and Thaivalappil, 2018) A manufacturer of gluten free pre-packaged
foods was prosecuted after their products were found to contain significant amounts of gluten.
More recently New Zealand found gluten in several food products labeled “gluten free”(Halmos
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et al., 2018). Because not every CD patient has clinical symptoms immediately after ingestion
of gluten, they may not know they have been exposed to gluten until they develop complications
like malabsorption or cancer. There is research that a handheld gluten detector created by
Nima in 2019 read 20ppm gluten, the limit set by the FDA, with some success at lower
concentrations.(Zhang et al., 2019)
The only viable treatment showing continuous success in ameliorating the ongoing
damage caused by CD is GFD. The reaction and adherence to a GFD varies dramatically in
CD patients. Some patients can indeed handle a miniscule amount of gluten, where others
must avoid it to the extent that breathing it could be hazardous. Similarly, some patients react
to the Avenin in oats, sparking a CD reaction just as with gluten(Hardy et al., 2015). Others do
fine eating GF oats. (Fric et al., 2011; Hardy et al., 2015; Kilmartin et al., 2003; Londono et al.,
2013; Tapsas et al., 2014)
The presence of gluten is another topic of debate. The FDA regulations state that 20
ppm gluten or less is required to label a product gluten free. Since this is not always tested,
reading the ingredient list on products is the safest alternative. In this case, any gluten related
substances are eliminated since most labels only inform below the 2% cut off line, and the cut
off for FDA gluten free is 0.002%. This vigilance is not only limited to food. Other substances
such as medication and cosmetics use gluten on a regular basis and must be inspected as
well.(Durham and Temples, 2018; Martin, 2008)
Table 3: General Gluten-Free Diet(Martin, 2008)

Milk products

recommended
Milk
cream
buttermilk
plain yogurt
cheese
cream cheese
processed cheese
processed cheese foods
cottage cheeses

Question
milk drinks
flavored yogurt
frozen yogurt
sour cream

not allowed
malted milk
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Table 3 cont.

Breads

cereals

Pastas

recommended
products made from
Corn, rice or soy flour
Starch from Corn, Potato
buckwheat
cornmeal
millet
flax
teff
sorghum
quinoa
amaranth
rice bran
arrowroot or potato flour
tapioca or pea flour
cream of rice
soy cereal
hominy
brown/white rice
puffed corn/rice/millet
see breads
Fresh
frozen

Meats
salted
smoked
eggs
Eggs
lentils
chickpeas
beans
Other proteins
nuts
seeds
tofu
fresh
frozen
Fruits/vegetables
canned

Soups

Homemade broth
GF bouillon cubes
cream soups

Question

rice/soy pablum

not allowed
products containing
wheat
rye
triticale
barley
oats
wheat germ/bran/starch
bulgar
granham flour
gluten flour
durum flour
farina, kamut
semolina
spelt
see breads
added malt
extract/flavoring

canned
preserved
pre-prepared

containing Hydrolyzed
vegetable protein (HVP)
containing Hydrolyzed plant
protein (HPP)

egg substitutes
dired eggs
egg whites
Baked Beans
dry roasted nuts
peanut butter

pie filling
dried fruits
fried potatoes
scalloped potatoes
canned soups
dried soup mixes
bouillon cubes

battered dipped

containing HVP
containing HPP
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Table 3 cont

recommended
butter
margerine
lard
Fats
vegetable oil
cream
shortening
homemade salad dressing
ice cream
sherbet
ice
Desserts
whipped toppings
custard
gelatin deserts
GF homemade pastries
tea
instant and ground coffee
cocoa
soft drinks
Beverages
cider
distilled alcoholic beverages
wines
pure liqueurs
Snacks
popcorn
pickles
relish
olives
ketchup
condiments
mustard
tomato paste
vinegar
GF soy souce
pure cocoa
baking cocoa
choc chips
carob chips/powder
monosodium glutamate
Other
cream of tartar
baking soda
yeast, Brewers yeast
coconut
aspartame

Question
salad dressings
mayonaise
communal butter dish

not allowed
packages suet

Milk pudding
custard powder
pudding mixes
pies

ice cream cones/wafers
any desert made with
ingredients listed in Breads

instant tea
coffee substitutes
fruit flaovred drinks
chocloate mixes
flavored/herbal tea

beer
ale
lager
cereal malted beverages

flavored anything
herbs/spices
soy sauce
worchestshire
mixed spices

mustad pickles
imitation pepper

baking powder
sauces
gravy
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Future treatments
One of the ongoing debates on CD focuses on screening the population. As stated,
even though 1% of the population suffers from CD, in the USA only 3% of that, or 0.3% of the
total population, has received that diagnosis. There are several screening tests, however the
criteria for active CD differs between countries and its onset is not always noticed immediately.
With a prevalence this high, screenings in patients with related diseases or conditions is
recommended, but the debate for larger screenings is ongoing. In 2017, the American Medical
Association reviewed the possibility for adult screenings and found the current evidence is
“Insuffucient to assess the balance of benefits and harms of screening for Celiac Disease in
asymptomatic persons” (Force et al., 2017). (Evans et al., 2011; Force et al., 2017; Hujoel et
al., 2018)
Vaccines have been considered for this using antigen-specific immunotherapy(ASIT) or
epitope-specific immunotherapy(ESIT). ASIT has been successfully used for allergy reactions,
specifically the CD4 T-cells reactions with MHC class II. Since CD is closely related with HLADQ2/DQ8 in this interaction, it would be the target for such a vaccine. This research is slowed
by the difficultly in monitoring the T-cells in research subjects. A recent trial with Nexvax2
showed progress.

Participants showed no adverse reaction to the vaccine and “resulted

nonresponsive to a further oral gluten challenge”(Di Sabatino et al., 2018).

Although this

vaccine is only targeting HLA-DQ2.5, it is a step in the correct direction.(Anderson and Jabri,
2013; Di Sabatino et al., 2018)
Diagnosis
Symptomatic
In children, efficient and reliable diagnosis is achieved through an assessment of the
symptom cluster and its relief based on GFD implementation. Children with CD have several
classic symptoms that reliably improve upon the start of a gluten-free diet; anorexia, failure to
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thrive despite adequate diet, chronic/recurrent diarrhea, irritability, abdominal distension, weight
loss and muscle fatigue. Often these symptoms cause the child to be examined and treated,
but then the symptoms reoccur unless a GFD is initiated. Currently, the subsequent visit alerts
the medical professionals to an unknown underlying cause, and CD is often diagnosed at this
point.(Burkhardt et al., 2018) This is valid in infants as well. The primary issue is the damage
done between the initial visit where the symptoms are treated and the following visit where the
underlying cause of the presence of gluten in the diet is treated.(Marginean et al., 2018)
Childhood symptoms change slightly in adults. Weight gain is actually rather common in
CD due to the increased need for food intake to meet the higher nutritional requirements. Long
term malnutrition symptoms such as severe anemia, arthritis, aphthous stomatitis, dental
enamel defects, and short stature are less common in children, but more common in adults
possibly due to the developmental stages children experience.

Additional neuropathic

symptoms that present at any age include autism, ataxia, dementia, depression, epilepsy,
headaches, peripheral neuropathy, and schizophrenia(Burkhardt et al., 2018).
Another common symptom is comorbid conditions in the immune system. CD frequently
exists alongside Type I diabetes, WIlliams Syndrome, Turner's syndrome, Down Syndrome,
arthritis and several autoimmune disorders such as thyroid and liver autoimmunities. Up to a
quarter of diagnosed CD patients have dermatitis herpetiformis(DH), which is also increasing in
prevalence. DH, a rash that leaves purple marks even after lesions and sores have healed,
occurs when IgA pools in the skin on the knees, elbows, back or buttocks.
Serology
The more common, and least resource expensive method of diagnosing CD is the
serology presence of IgA tTG2 and IgA endomysial antibodies in the bloodstream when the
patient has ingested gluten for a prolonged period of time. The serological cascade usually
includes total IgA concentration, tTG2 antibodies (either IgA or IgG), deamidated gliadin
antibodies, and endomysial antibodies.

Endomysial antibodies are located in the muscle
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primarily and target transglutaminases. These are detected using Indirect Immunofluorescence
Assay and Immunoturbidimetric Immunoassay.
Over the last few years, a controversy has risen over the diagnosis of CD.

The

presence of Antibodies in serum originally confirmed the diagnosis. However, in 2005, the
North American Society for Pediatric Gastroenterology Hepatology and Nutrition(NASPGHAN)
required an intestinal biopsy, a policy further supported by American College Gastroenterology
in 2013 and British Society Gastroenterology in 2014. Both groups require an endoscopy in the
duodenal for adults to confirm a diagnosis of CD. Currently the European Society for Pediatric
Gastroenterology, Hepatology and Nutrition (ESPGHAN) remains the only group to endorse
serum-only diagnosis.

Due to procedural risk, diagnosis in children remains serum-based.

However, variability in testing kits and lab practices sometimes makes this unreliable. Thus,
symptomatic children are diagnosed with serum testing, and most of the times, genetic testing is
recommended. To further control the diagnosis rate, the level of antibody-TG in the serum used
is 10x normal where any patient below this cutoff, but still a strong candidate for CD diagnosis
will undergo a biopsy. For symptomatic patients, a cutoff of 10x had a positive predictive value
of 98%, leaving only asymptomatic patients misdiagnosed. For adults, there is some debate
over the cutoff. One study showed 100% PPV at 5x, while another showed different kits had
different cutoffs for 100%PPV.(Kowalski et al., 2017; Turner, 2018)
An additional point in the argument against serum-only diagnosis in adults is the
baseline information of lesions acquired during the endoscopy. Approximately a third of CD
adults continue to have lesions for 2-5 years following the initial diagnosis and adoption of an
assumed gluten free diet for the same period of time. Since the long term risks of this damage
to the mucosal layer are unknown, not only does the biopsy provide information about the
current state, but it also indicates refractory CD. The rules surrounding the diagnosis via biopsy
are variable. Another approach is referred to as the 4 out of 5 approach. If 4 of these 5 events
are true, then CD diagnosis could be accepted; CD symptoms, a positive response to a GFD,
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positive serology for IgA TTG -antibodies/EMA, biopsy, and genetic HLA testing(Burkhardt et
al., 2018).

Regardless of diagnosis, repeated biopsies to monitor the intestine are

recommended once CD is confirmed. A need for greater understanding of this diagnosis is
clear.(Burkhardt et al., 2018; Turner, 2018)
Endoscopic
The most trusted test for CD currently is endoscopic duodenal biopsy. “One to two
[samples] from the duodenal bulb and no less than four from the distal duodenum”(Turner,
2018) represents the varied enteropathy of the duodenum. Initial histology includes plasma
cells infiltrating the mucosa. Further along, a crypt hyperplastic reaction is found and then
blunting of the villi as they are remodeled. Other factors such as gluten intake and proximity to
Brunner‟s glands must be taken into account during this interpretation. The levels and size of
these reactions which constitute a diagnosis of CD are under considerable investigation still.
There are 2 systems of classification for the results of an endoscopy; the Marsh scale
and the Oberhuber scale. The two scales focus on different progressions of the condition are
shown in Figure 7. The Marsh scale focuses on the condition in a linear fashion from healthy to
villi atrophy and intestinal damage, with 0 being normal and Type 2 destructive being full CD.
The Oberhuber scale focuses more on the amount and severity of the damage, again with 0
being healthy normal tissue, but then type 3 is divided into categories based on fraction of
damage and type 4 is complete atrophic lesions with no inflammation or other villi character.
(Dickson et al., 2006; Kowalski et al., 2017; Martin, 2008)
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Figure 7: Pathologic Classification of Celiac Disease(Martin, 2008)

Genetic
At this time, genetic and CD research have identified MHC genes as the most important
genetic component in CD. As stated in the section describing the creation of B-Cells, MHC
genes control the immunoglobulin presented on the surface of the B-cells and control the
selectivity of the reaction to antibodies. In 80-95% of CD diagnosed patients, the MHC gene
HLA-DQ2 variant exists. Those who are negative for this gene generally express the other
MHC gene associated with CD, the HLA-DQ8 variant. Only 1% of CD patients present neither
of these genes compared to nearly half the general population. A large number of patients
express both. Due to this correlation, HLA typing specifically for the allele responsible for the
above genes indicates predisposition towards CD. The alleles responsible for HLA-DQ2 variant
are HLA-DQA1*05 and HLA-DQB1*02, and for HLA-DQ8 variant, HLA DQA1-03 and HLA
DQB1*0302. The common genotyping done is for HLA-DQA1*05 and HLA-DQB1*02.(Jabri and
Sollid, 2006) Genetic testing supports a diagnosis, or lack thereof, but due to the population
that expresses these phenotypes with no other CD indicators, genetic-only diagnosis for CD is
considered invalid.
Further evidence exists of genetic components beyond the MHC genes for CD. In Italy,
a paper showed that the concordance rate between monozygotic twins was 75%, but a study in
Spain also showed that the concordance between HLA-identical siblings was only 25%(Jabri
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and Sollid, 2006).
phenotyping.

This implies that there is a strong genetic factor beyond the HLA

In 2003 Babron published a paper identifying chromosome 5 as a possible

location for one such gene, and van Belzen published a similar finding on chromosome 19 that
same year(Jabri and Sollid, 2006). One paper suggested myosin IXb on chromosome 19 to be
a candidate, however further attempt to replicate the work failed. This gene attracted interest
due to its production of actin-binding myosin. Theoretically, this could increase permeability in
the intestine walls, an important characteristic of CD. Additionally, another group found cells of
myeloid origin expressed myosin IXb, possibly affecting APC function.(Jabri and Sollid, 2006)
A study in 2007 noted a relationship between CD and certain genes involved in the
production of IL2 and IL21. “IL2-21 locus is now a well-established disease susceptibility locus
for T1D, RA, UC, MS, and systemic lupus erythematosus (SLE)”(Kumar et al., 2012). This
study identified 13 loci that could participate in CD. In 2010 a larger cohort genetic study noted
another 13 loci outside the HLA genes that correlate with CDs.

Furthermore, this study

identified 14 loci shared between CD and RA(arthritis), including 4 previously unknown loci.
The introduction of the immunochip in 2011 added 13 more loci correlated with CD. In this
study, of the 39 total loci associated with CD, 13 included multiple independent signals, bringing
the total of actual independent loci to 57. In the same year, research discovered 4 loci that
overlap with Crohn‟s Disease.(Kumar et al., 2012)
One gene under close scrutiny is the PTPRK gene, part of a loci that regulates thymic Tcell selection. Another gene, possibly a causal gene, is IL18RAP, which does not show an effect
on nearby genes but strongly implies CD is governed by gene expression deregulation. Studies
show that 50% of CD related SNPs affect the expression of nearby genes, thus implying that
CD is caused by or has an effect on gene expression regulation. However, research also
shows that affecting a gene not nearby could prove important. Eighteen unlinked pairs located
affected the regulations of the same trans-gene in CD, implying the importance of this genetic
behavior in the disease mechanism. In fact, HLA contain and probably rely on this behavior.
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These genes are often related in their function. Functionally related genes tend to respond to
the same or similar regulation pathways and thus “CD loci is associated with T-cells (TAGAP,
TNFRSF14, CCR4, CTLA4, UBASH3A, and CD28), NK cells (UBE2E3, RUNX3, FASLG,
PTPN2, and IL18RAP), neutrophils (PLEK and CCR3), and B-cells (BACH2, SOCS1,
POU2AF1, ICOSLG, IRF4, CIITA, ZFP36L1, and CSK)”(Kumar et al., 2012).(Kumar et al.,
2012)
Of the 57 loci, only 3 appear related to protein sequencing. In fact, 16% appear to have
no connection to protein-coding genes, and 95% are located in the gene regulating regions.
The majority seem to related to introns or the intergenic regions, meaning they affect the
transcriptional regulations of the genes. Much of the effect seems focused on non-standard
RNA and, thus, part of gene regulating and splicing. (Kumar et al., 2012)
Since the CD population overlaps with certain other conditions such as Addison‟s or IgA
deficiency, the genes involved in those situations could indicate CD. Further study is needed for
this.
Also, since there is a genetic component, many advocate for screening of first-degree
relatives of a confirmed case at least with serology. Between siblings, the rate is 8.4% and
offspring is 7.9%. Oddly, the rate of parents of active CD patients is at 3%, lower than most
other relatives.(Burkhardt et al., 2018)
Other
Several other methods of diagnosis have been attempted. Soler et al developed a SPR
biosensing immunoassay for urine that detects residual 33-mers, something that should only be
present in an untreated CD patient. This method utilizes specific monoclonal antibodies and
demonstrated the ability to quantify gliadin peptides without extraction or purification with a limit
of detection at 1.72 ng/ml (CD patient is 20 ug/ml). Additionally, this method is a practical, noninvasive test of the adherence to GFD of the patient.(Soler et al., 2016)
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There are some general GI issues that occur during CD that when combined indicate
further testing is necessary for CD. In one case, an infant presented mild pericardial effusion
with lack of accompanying cardiac pathology but abdominal bloating, irritability, intermittent
diarrhea, and diffuse abdominal tenderness. Lab tests revealed anemia, hypoalbuminemia,
leukocytosis, and high transaminases and inflammatory biomarkers.

The diagnosis agreed

upon was E-Coli and treated until a return visit for the 1-year-old a month later with the same
symptoms and same lab tests. The child was admitted with the same severity 8 months later
and tests showed serum Anti-tTG2 8x normal and duodenum modifications Marsch 3C stage.
In this case, this child likely suffered 8 months additional damage and malnutrition at an age
when the impact would be extreme.

That could‟ve been avoided if there was a sufficient

diagnosis for CD.(Marginean et al., 2018)
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CHAPTER 5: RAMAN SPECTROSCOPY
Discovery
Raman Spectroscopy(RS), named for Sir CV Raman who first observed the
phenomenon in 1928, utilizes the inelastic scattering of molecular excitations to calculate
vibrational modes in a system based on the energy shifts displayed during the scattering. This
is generally accomplished using a laser to cause shift in energy states and then the resultant
energy discharge during the return to equilibrium is captured and interpreted.

During this

process additional energy is released in the form of Elastic or Rayleigh shifts, which are filtered
out by a frequency filter such as a band pass filter.
Stokes and anti-Stokes shifts are inelastic shifts. When the energy of the laser (or
another source) hits the excitable particle, it jumps to a virtual energy level. Rather quickly, it
returns to an energy level at or near its previous state. When this new energy level does not
match the previous level, this is inelastic shift. A Stokes shift is when this new level is higher
than the original energy level and anti-Stokes shift is when this new level is lower than the
original level. The process where the release is elastic or the energy level is the same as the
original level is called Rayleigh shift(see Figure 8). When the return is Stokes or Anti-Stokes,
the energy change occurs in the photon that excited the molecule and is known as raman
scattering.(Ember et al., 2017)
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Figure 8: Energetic Transitions(Ember et al., 2017)

A raman spectrometer has several basic components. The first is a monochromatic
laser. The wavelength of the specific laser affects the sensitivity and resolution of the sample.
Additionally, certain types of bonds react with different wavelengths, i.e. biomaterials and
fluorescence suppression have better optimization in lower wavelengths (<400 nm). However,
the extreme damage prevents its use on live samples due to the higher energy. This means
that more often higher wavelengths in the visible or IR range are used, decreasing the intensity
of the signal. This decrease in signal intensity and associated signal to noise ratio (SNR)
resulting in less information gathered remains a key roadblock in the widespread usage of this
technology.
Following sample interrogation, the resultant energy is directed to a collation mirror via a
series of lenses to reflect the energy through a diffraction grating or another device which
diffracts the energy into distinct wavelengths. Then the energy is passed through a series of
focusing mirrors and lens until the resultant wavelength specific beams are fed into a detector
array. These series of mirrors and lenses are responsible for resolution control and signal noise
generation. Additional filters such as band pass filters are added to the machine to assist in
controlling the SNR and filtering out elastic shifts.

65
Types
There are several different techniques associated with Raman spectroscopy, each with
their own specialties. Below are four common types that may be of use in CD research.
Microscopic Raman Spectroscopy typically grafts a microscope on a raman
spectrometer and scans a sample in a raster style pattern. A uni- or multivariate spectral model
applied to the spectrum produces a complete readout of the information. Research shows that
a line pattern as opposed to a single-point pattern produces greater resolution at faster speeds.
In order to match the pattern of optical fibre to the laser pattern, the microscope can be coupled
using shuttering systems of optical fibers or masking arrays. Due to the sensitivity of this
approach, variations in baseline RS can hide diagnostically important discriminations.(Kong et
al., 2015)
Surface Enhanced Raman Spectroscopy (SERS) enhances the weaker signals by
utilizing metallic nanostructures to resonate with adsorbed or nearby molecules to enhance the
the raman scattering. This resonant interaction extends a few nanometers from the surface and
created a electromagnetic field that enhances raman bands 105 times. Additionally, tailored
nanoparticles conjugate targeted molecules, specifically antibodies, for a targeted scattering
enhancement. This has been done in tissues.(Kong et al., 2015)
Coherent anti-Stokes Raman Spectroscopy(CARS) uses multiple photons to produce a
distinct and more intense signal. Coherent Stokes Raman Spectroscopy is also possible. This
type may cause some change in the target and is used primarily for microscopy and combustion
diagnostics.
Tip-Enhanced Raman Spectroscopy, or TERS, is a form of SERS where the scattering
focus is on a sharp point, usually a gold tipped pin. This allows maximum resolution and
extreme targeting flexibility on the part of the researcher.

In order to properly use this

technique, the equipment set up requires a confocal or scanning microscope.
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Raman Spectroscopy has yielded many important scientific discoveries, notably in the
field of physics. More recently its application in identification of substance or the change in a
substance launched Raman Spectroscopy into several fields including medicine, security
sweeps and scientific analysis. Like many other optical systems, RS can measure changes in
real time, making its use in medical diagnosis and research all the more significant and vital.
(Ember et al., 2017; Kong et al., 2015; Kumar et al., 2016)
Diagnostics
Since the 2000s, Raman Spectroscopy has been an option for cancer diagnosis. Kirsh
et al published a method using RS to diagnosis and locate brain tumors with an accuracy of 250
µm(Kong et al., 2015). This label-free in-vitro probe measured tumors in mice. Later, using
raster scanning, spectra images correlated with H&E staining without the nearly dozen steps
involved prior to observation displayed tumor boundaries. Further use of CARS allows the
lower lipid count of the tumor to identify and clearly delineate the borders and infiltrations of the
tumor
In breast cancer, in-vivo techniques either provide numerous false positives or involve
biopsy results with more than 70% showing benign response. Recent work in RS showed that
the increase in intensity in the 788cm-1 and 1098 cm-1 spectra peaks distinguish cancer from the
surrounding tissue. In-vivo, TERS shows promise in decreasing the false positives from the
mammogram by using calcium hydroxyapatite, since many benign have calcium oxalate
instead.(Kong et al., 2015) However the depth of penetration for this technique is only 2-3 cm,
thus not deep enough for most breasts. Although preventative diagnosis is still impractical,
research shows that both in vivo and in vitro RS during surgery for tumor margin detection has
potential.(Kong et al., 2015)
Current diagnostic procedures for lung cancer also result in excessive false positives
interfering with reliable cost effective widespread screening. RS research predicted recurrence
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with a sensitivity and specificity in the 70% range.

By attaching RS to a bronchoscope,

identified neoplastic lesions with sensitivity and specificity in the 90% range.(Kong et al., 2015)
Prostate cancer research uses raman spectroscopy for diagnosis and identification.
Work in using RS for screening, biopsy, margin assessment and treatment monitoring continues
to progress, making use of RS to read DNA and RNA changes in cells. In 2002, a normal
prostate RS output was published.

It was later compared to various cellular hyperplasia,

including benign and adenocarcinoma, with good specificity.

Further research into early

detection proved not only viable, but able to distinguish between aggressive cancers in
serology.(Kast et al., 2014)
Other cancer research pursued RS as a viable method. Current research in skin cancer
and RS includes a hand held RS unit which can differentiate malignant and pre-malignant from
benign. The specificity of this research is still in its infancy. In the non-handheld versions, RS
successfully diagnoses skin cancer. More successfully, in vivo diagnosis of Esophagus cancer
using Raman fiber optic probes has shown a sensitivity of 91% and specificity of 94%. In
colorectal cancer, RS reveals more from the histopathology than current techniques provide,
mostly in the form of biochemical information.
Raman Spectroscopy research has the potential to yield specific results in bone disease,
including differentiation between brittle bone, osteoarthritis and other issues. The main obstacle
for in-vivo RS diagnosis is distance. Although RS shows great potential in this field, the depth of
penetration is still limited.
Diabetes testing may benefit from RS research moving forward. Currently, a blood test
is required in some form to measure blood glucose levels. Raman promises transcutaneous
measurements, already shown in mouse studies, which would provide a less invasive
measurement method for blood glucose.

Additionally, research into early diagnosis using

Raman spectra is underway and shows promise. SImilarly, early diagnosis for asthma and
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research into the molecular changes when becoming asthmatic use raman spectroscopy.(Kong
et al., 2015)
Limitations and advantages
Sampling is distinctly simpler with RS because the analysis samples are reagent and
label free with minimal preparation. There are fluorescence concerns which cause the use of
quartz, CaF or MgF as substrates simply due to their low intrinsic Raman signal. Glass, a
common material in labs, is very fluorescent and only recently has been successfully used in
RS. Since this is a biochemical analysis, the addition of reagents such as formalin or methanol
to fix the samples actually changes the outcome of the readings, making unfrozen un-fixed
samples optimal. (Ember et al., 2017)
This limits the reading to the life span of the sample at these conditions, however. Many
biochemical markers, such as proteins and cell structures begin to degrade when not fixed.
Furthermore, unfixed aqueous samples do not remain motionless, requiring the RS system to
accommodate such brownian motion in its calculations. This has given rise to research in
speeding up the RS data collection. Although a single Raman spectra integration is fast, a large
area and high resolution is time consuming. Raster scanning and slit scanning have decreased
the time needed. Also, “random sampling” and spectra averaging can be used to read large
chemical compositions when an entire system is not available for scanning, such as a
bloodborne issue.(Ember et al., 2017)
Quantization of RS is advantageous since the intensity of the signal is directly correlated
to the concentration of that molecule. General use is also restricted by cost and size of the unit.
The size of the machine has been decreasing in response to discovering these advantages.
Handheld devices are in testing and in production with various specificities and sensitivities.
Currently hand held devices are restricted in power and laser wavelength variability.(Ember et
al., 2017)
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History with cells
Research into inflammatory response using Raman spectra includes measuring and
quantifying C-reactive protein produced by inflammatory immune cells in blood plasma.
Additionally, level of fibrinogen and heparin are detectable by RS. This shows that the immune
system has markers RS can detect.(Kong et al., 2015)
Brown et al uses RS for immunology study on T-cells. For certain T-cells, the activation
of CD28/CD3 interaction indicates possible rejection of tissue implant. By comparing active,
inactive and resting T-cells, Brown, et al. demonstrated that activation of this ligand pair
expressed itself in RS as an increase in intensity in several peaks, but most significantly in the
1182:1195 region. When compared to alloreactive T-cells, this region showed a similar change,
meaning this region identifies activated T-cells. During this comparison, the spectra differed
greatly in 6 peaks; 903 cm, 1031 cm, 1093cm, 1155 cm, 1326 cm, and 1449 cm.

The

discriminant function of this research showed a clear difference with 100% accuracy meaning
that all reactivity could be identified separately from CD28/CD3 activation.

Moreover,

comparing the peaks to established RS, we can identify specific peaks representing specific
changes. Similarly, T-cell regulated apoptosis is also identifiable under RS, specifically in CD8+
T-cells. The apoptosis-related DNA signals show clear changes as the resting CD8+ T-cells
activate and mature.

Although certain proteins are also easily discernible, research

demonstrates that DNA changes, not protein expression, track better using RS. This RS can
also differentiate between T-cells and B-cells in the immune system. (Brown et al., 2014; Brown
et al., 2009; Ichimura et al., 2016; Lee et al., 2015)
Even though RS displays changes in DNA more clearly, RS can successfully monitor
changes in activated T-cells as expressed proteins interact with antibodies. Further research
into the activation of CD69, CD25 and CD71 on T-cells demonstrated RS could detect different
stages in activation. This correlates with previous research on activation and shows RS as a
viable method to continue this research forward. Additionally, RS can identify different protein
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markers and nuclei changes in real time in T-cells which could greatly advance understanding
and research into T-Cell activity and diagnosis in T-Cell related conditions. (Brown et al., 2014;
Brown et al., 2009; Ichimura et al., 2016; Lee et al., 2015)
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CHAPTER 6: IN SUMMARY
Nutrition
Food eaten undergoes extensive digestion by multiple enzymes and proteases between
the mouth, stomach and small intestines in order to produce chyme in a form that can be
absorbed. The majority of the absorption is completed in the jejunum of the small intestine,
largely due to the extensive surface area of the endothelium by combining the ventuoles, villi
and microvilli. Food not absorbed in the jejunum, along with bile from the gall bladder, is
absorbed by the Ileum or pushed into the colon for excretion.
Immune System
The majority of the reaction in CD uses B-cells and T-cells. B-cells develop in the bone
marrow, producing IgM and IgD immunoglobulins on their surface prior to leaving the bone
marrow stroma. The T-cells develop in the thymus, also producing immunoglobulins called
either γδ or αβ, which exist next to either CD4 or CD8 ligand. These are designed to bind tightly
to MHC on an APC and activate to assist in an immune response.

CD8 T-cells primarily

activate cytotoxic immune reactions, such as NK cells and Macrophages. CD4 T-cells primarily
activate B-cells through ligand interaction, which in turn starts an adaptive immune response.
Both T-cells and B-cells can form memory cells which remain following an immune reaction to
increase the reaction speed and magnitude on subsequent invasions by similar antigen. Γδ Tcells have special interactions that are not fully understood yet.
Mucosal Immune
The mucosal system contains a unique collection of the immune system in that it is
divided into effector and inductor sites. These systems also have an initial defense in the form
of mucin and primarily focus on preventing the endothelium from being breached or damaged.
Crossing the endothelium of the gut requires assistance, and once across, the invading particles
are inundated with cellular immune reactions. Furthermore, mucosal immunity maintains its own
memory, utilizing a plethora of IgA antibodies to patrol the mucin layer as well as past the
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endothelium. In CD the interaction of a polypeptide with the crosslinking protein tTG2 causes
the adaptive immune response.
Gluten
Gluten is a water insoluble protein present in Wheat, Rye, Barley and Spelt that contains
various proline rich bonds, reducing the body‟s ability to digest the polypeptide.

Certain

fragments, specifically 13mer, 19mer, 26mer, and 33mer, cause immunogenic reactions within
the gut of a CD patient. The 13mer and 19mer are cytotoxic and activate the killer pathways in
CD8 T-cells lining the endothelium of the gut. Both 26mers and 33 mers bind tightly to tTG2
and this combination binds to ligand on APCs and activated the CD4 T-cells. In turn, this
activates the adaptive immune system. It results in damage to the endothelium, specifically loss
of villi architecture, and thus nutrition absorption, and an increase in immunogenic tTG2
throughout the body.
Symptoms
Symptoms of CD vary considerably by age, gender and environment.

In children,

particularly infants, symptoms include failure to thrive, chronic diarrhea, vomiting, abdominal
distension, muscle wasting, anorexia and irritability.(Troncone and Jabri, 2011)

As age

increases and/or the length of disease process increases, the symptoms relate heavily on the
lack of nutrition caused by the condition. Anemia and Osteoporosis are common side effects of
this nutritional deficiency. (Troncone and Jabri, 2011) Additional health problems related to this
malnutrition range from manageable, such as short stature, arthritis, alopecia, aphthous
stomatitis and dental enamel hypoplasia, to dangerous conditions such as various
endocrinopathies,

epilepsy

with

bilateral

occipital

calcifications,

neuropathies

and

cardiomyopathy. (Troncone and Jabri, 2011) Additionally, CD is significantly correlated to a
variety of immune disorders such as diabetes, Addison‟s disease, Down‟s syndrome, Turner‟s
syndrome, William‟s syndrome and a plethora of autoimmune diseases. (Troncone and Jabri,
2011)
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Diagnosis
The majority of patients are diagnosed symptomatically, meaning physicians notes that
their patient recover their health in the absence of gluten. As this mostly works for the extreme
symptoms, other methods of diagnosis are now used. Serology is the most common method of
testing CD as a possible pathology, being both inexpensive and quantitative.

The more

expensive and more accurate diagnosis results from a biopsy of the duodenum and jejunum,
looking for the damage to villi characteristic of CD.

There are some genetic prevalence,

however research has not verified the genetic components necessary to make genomic testing
a viable diagnosic test. This research is ongoing.
Raman Spectrocopy
Raman uses the combination of energy emissions and inelastic scattering to interrogate
a substance.

The information gained informs on molecular geometry and allows detailed

information on the substance to be gleamed. Its use in medicine, particularly diagnostics is well
developed, with an increased number of cancers being studied. Research shows that Raman
spectroscopy has the ability to read the changes a T-cell undergoes during activation, thus
providing information on the changes to the cell on a molecular level.
Future Research
There are many avenues of research still needed for CD as a condition.

What

environment triggers the activation of CD, and how does it influence the symptoms of the
patient? What is the early stage of CD; is there an order to the immune interaction? Why do
CD patients digest gluten in the first place when it seems non-CD patients lack this activity? Of
all these questions, the question of diagnosis may be the most pressing one. How can we
diagnose CD in a patient without damaging them further by forcing them to ingest gluten? CD is
not a condition that disappears once a GFD is achieved, only the symptoms are ameliorated.
There must be some sort of memory or physiological signal remaining.

Normal immune

memory involves an antibody or TCR remembering an interaction. However, this condition

74
utilizes non-specific TRC on CD8 T-cells and requires an immunogenic reaction with tTG2 for
CD4 T-cells. One is not a memory function by virtue of being non-specific, and the other
disappears. Otherwise, the serology test would not require the presence of gluten to give a
positive result. There are three major changes that seem to maintain following a GFD: the
bone osteoclasts continue at a higher that baseline rate, the serological concentration of brainderived neurotropic factor is increased, and the prevalence of γδ T-Cells is considerably higher
in a CD patient even after a GFD is achieved. Raman Spectroscopy has shown to be a viable
method in investigating T-cells, and as such, may prove valuable in this line of research.
Moving forward, I would like to understand the differences in celiac patients post
condition activation in an effort to advance the diagnostic technology. Specifically, immune
memory, which exists mostly in T-cells and B-cells, could hold the key to removing the necessity
of gluten ingestion from celiac diagnosis. As RS has already demonstrated functionality in this
vein, I propose that there are morphological, molecular, or protein and DNA expression
differences in T-cells and B-cells post celiac reaction that will be apparent under RS when
compared to that of a healthy patient.
An experiment utilizing microfluidic chip technology designed to immobilize and control
the cells and their interactions would be used to allow RS interrogation. Using photolithography
to microfabricate a device to trap an active, living cell is possible. Several studies have already
isolated a single cell for drug research, cell study and diagnostic purposes (Tan and Takeuchi,
2007). Furthermore cellular electropotential is a method of immobilizing cells for research.
Many mammalian cells have been immobilized in this fashion, including plasma cells, platelets,
and cancer cells(Yafouz et al., 2014). The chip design would isolate a single T-cell or B-cell for
RS interrogation. It could be further designed to allow for interaction between these cells for
study (see Figure 9).
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Figure 9: Initial Microfluidic Device Design.

Initial tests would involve fresh T-cells and B-cells from CD patients both on and off GFD
compared to similarly collected cells from healthy patients. Ideally, an interaction between the
specific gluten polypeptides and the various important immune cells could be studied in the
same environment. For the purposes of this research, the focus would be to obtain CD4+ Tcells, CD8+ T-cells, γδ T-Cells, and mucosal B-cells for comparison.
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ABSTRACT
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Celiac Disease is a condition whereby ingesting Gluten causes an autoimmune reaction
in the intestines with adverse effects throughout the body. Although statistic analysis estimates
that 1% of the general population is affected by this condition, the diagnosis and treatment
research lacks in key areas of understanding. This is a summary of current research and
physiological information on the impact of Celiac Disease. In the last twenty years, Raman
Spectroscopy assisted in diagnosis and treatment of various other ailments.

In this case,

Raman Spectroscopy can be used to research immunological cells involved in Celiac Disease
and further research.
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